Stockwinners Market Radar for March 21, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

MESO

Hot Stocks

21:28 EDT Mesoblast says FDA schedules pre-license inspection of Remestemcel-L production - The company states: "Mesoblast Limited announced that, as part of the ongoing review of the BLA for remestemcel-L in the treatment of children with SR-aGVHD, the FDA has scheduled a Pre-License Inspection of Mesoblast's cell therapy manufacturing operations at Lonza Bioscience in Singapore. On March 7, 2023, the FDA accepted the Company's resubmission of the BLA for remestemcel-L and set a PDUFA goal date of August 2, 2023. Remestemcel-L has FDA Fast Track designation, a process to facilitate the development and expedited review of therapies for serious conditions that fill unmet medical needs, and Priority Review designation, which is given to drugs that treat a serious condition and provide a significant improvement in safety or effectiveness over existing treatments. Survival outcomes have not improved over the past two decades for children or adults with the most severe forms of SR-aGVHD.1-3 The lack of any approved treatments for children under 12 means that there is an urgent need for a therapy that improves the dismal survival outcomes in children."
AFCG

Hot Stocks

20:08 EDT AFC Gamma CEO buys $369K in common stock - In a regulatory filing, AFC Gamma disclosed that its CEO Leonard Tannenbaum bought 26K shares of common stock on March 8th in a total transaction size of $369K.
COIN

Hot Stocks

20:03 EDT Cathie Wood's ARK Investment sold 161K shares of Coinbase today
ONEW

Hot Stocks

19:38 EDT OneWater Marine CEO buys $240.9K in common stock - In a regulatory filing, OneWater Marine disclosed that its CEO Philip Austin Singleton bought 10K shares of common stock on March 17th in a total transaction size of $240.9K.
LGIH

Hot Stocks

19:01 EDT LGI Homes announces new community in North Carolina - LGI Homes announced the grand opening of its newest community, New South Bridge, located in Bolivia, NC. "With the opening of New South Bridge, we are excited to expand our presence further into the Wilmington market," said Jef Yarbrough, division president. "The new homes available at New South Bridge provide homebuyers in the Bolivia area with an incredible selection of affordable, move-in ready opportunities that offer the space, upgrades and amenities they desire."
ALVOF

Hot Stocks

18:43 EDT Alvopetro Energy raises quarterly dividend 17% to 14c per share - Alvopetro Energy announced a 17% increase in its quarterly dividend, to 14c per common share.
PYXS PFE

Hot Stocks

18:21 EDT Pyxis Oncology discloses $5M purchase of common stock by Pfizer - In a regulatory filing, Pyxis Oncology (PYXS) disclosed that Pfizer (PFE) bought 1.8M shares of common stock on March 17th in a total transaction size of $5.0M. Shares of Pyxis Oncology are up 26% afterhours at $2.78.
CDNS

Hot Stocks

17:55 EDT Cadence Design CEO sells $5.33M in common stock - In a regulatory filing, Cadence Design disclosed that its CEO Anirudh Devgan sold 25.7K shares of common stock on March 17th in a total transaction size of $5.33M.
EFC

Hot Stocks

17:51 EDT Ellington Financial announces $50M stock repurchase program - Ellington Financial announced that its Board of Directors has authorized the repurchase of up to $50M of the Company's common stock. This authorization extends the Company's ability to repurchase common stock beyond the 1.55M shares previously authorized in 2018. Through March 21, the Company has repurchased nearly all of the 1.55M shares previously authorized.
LMT

Hot Stocks

17:50 EDT Lockheed Martin awarded $119.98M Navy contract modification - Lockheed Martin was awarded an $119.98M cost-plus-fixed-fee, firm-fixed-price, cost reimbursable, indefinite-delivery/indefinite-quantity contract to provide logistics, engineering and modification install support for the H-53 helicopter for the Marine Corps, Navy, and Foreign Military Sales customers. Work is expected to be completed in March 2028. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. This contract was not competitively procured pursuant to 10 U.S. Code 2304. The Naval Air Systems Command is the contracting activity.
TRN

Hot Stocks

17:44 EDT Trinity Industries Director MacLin buys 4,500 shares of company stock - Director of Trinity Industries Samuel MacLin disclosed in a regulatory filing that he had purchased 4,500 shares of company stock at $21.19 per share on March 17 for a total transaction amount of $95,355.
KFS

Hot Stocks

17:15 EDT Kingsway Financial board authorizes buyback for up to $10M in common stock - Kingsway Financial announced that its Board of Directors approved a share repurchase program that authorizes the Company to repurchase up to $10 million of its common stock. The share repurchase program will have a one year term.
SSTI

Hot Stocks

17:12 EDT ShotSpotter CEO Ralph Clark sells over $353K in company shares - The CEO of ShotSpotter Ralph Clark disclosed in a filing, that he sold 9,786 shares of company stock at $36.08 per share on March 17 for a total transaction amount of $353,089.
VERA

Hot Stocks

17:11 EDT Vera Therapeutics director buys $637K in common stock - In a regulatory filing, Vera Therapeutics disclosed that its director Beth Seidenberg bought 89.3K shares of common stock on March 17th in a total transaction size of $637K.
ALPMY

Hot Stocks

17:05 EDT Astellas reports 'positive' findings from Phase 3 GLOW trial - Astellas Pharma will present detailed results from the Phase 3 GLOW trial evaluating first-line treatment with zolbetuximab, an investigational first-in-class Claudin 18.2 targeted monoclonal antibody, plus CAPOX versus placebo plus CAPOX in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. In the study, investigational treatment zolbetuximab plus CAPOX demonstrated a statistically significant improvement in progression-free survival compared to placebo plus CAPOX. Specifically, zolbetuximab plus CAPOX reduced the risk of progression or death by 31.3% compared to placebo plus CAPOX, meeting GLOW's primary endpoint. Median PFS was 8.21 months in the treatment arm and 6.80 months in the placebo arm. The study also showed that zolbetuximab plus CAPOX significantly prolonged overall survival, a key secondary endpoint, reducing the risk of death by 22.9%. Median OS was 14.39 months and 12.16 months for the treatment arm and placebo arm, respectively. The incidence of serious treatment-emergent adverse events was similar between both arms and consistent with previous studies. The most frequent TEAEs in the GLOW study were nausea, vomiting and decreased appetite in the zolbetuximab versus placebo arms. "The progression-free and overall survival data from GLOW demonstrate the potential of zolbetuximab in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric and gastroesophageal junction cancer," said Rui-Hua Xu, M.D., Ph.D., Professor in the Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China, and the primary investigator of GLOW. "While the treatment landscape is continuing to evolve, patients at this stage of the disease are in need of options and the GLOW data are encouraging for this patient population."
SPLK

Hot Stocks

17:04 EDT Splunk board member Sean Boyle to resign from board effective March 16 - On February 20, Sean Boyle informed the Board of Directors of Splunk of his resignation as a member of the Board of the Company, effective March 16 . Mr. Boyle's decision was not due to a disagreement with the Company. In connection with Mr. Boyle's resignation from the Board, the Board decreased the authorized number of directors on the Board to ten directors, effective as of March 16.
NB

Hot Stocks

17:00 EDT NioCorp begins trading on Nasdaq - NioCorp Developments is pleased to announce that its stock began trading on the Nasdaq Stock Market on 3/21 under the ticker symbol "NB." A class of NioCorp warrants also is trading on the Nasdaq under the ticker symbol "NIOBW." NioCorp's shares will continue to trade and will be cross-listed on the Toronto Stock Exchange under the ticker symbol "NB."
WAVD

Hot Stocks

17:00 EDT WaveDancer to immediately pursue strategic alternatives - WaveDancer announced that it will work with its advisor, B. Riley Securities, to immediately undertake a review of additional strategic options available to the company including a merger or possible sale. "In addition to improving cash flow, the sale of GMI provides the Company with a cash infusion that will allow us to consider a range of options that would have otherwise been foreclosed," said CEO Jamie Benoit. "Now that we've eliminated the risk and expense of commercializing new technology, we can evaluate various strategic alternatives including a business combination or a sale."
WAVD

Hot Stocks

17:00 EDT WaveDancer trading resumes
WAVD

Hot Stocks

16:59 EDT WaveDancer closes majority investment in Gray Matters - WaveDancer announced that it has sold its blockchain-enabled supply chain management software subsidiary, Gray Matters, Inc. to Gray Matters Data Corporation, whose lead investor is venture capital firm StealthPoint, LLC. StealthPoint and its investors will invest $3M of cash into GMDC with the option to invest an additional $1M within 90 days of closing. WaveDancer has retained an indirect 20% interest in GMI through stock in GMDC received at closing. In addition, WaveDancer received $1M of cash at closing and will receive annual contingent payments over the next seven years, up to a total of $4M. Importantly, the transaction will eliminate over $2M of annual WaveDancer operating expenses related to GMI.
PGRE

Hot Stocks

16:57 EDT Paramount Group Chairman Behler purchased $299K in company shares - The Chairman of Paramount Group Albert Behler disclosed in a regulatory filing that he had purchased 70,000 shares of company stock at $4.27 per share between March 17 and March 20 for a total transaction amount of $299,152. I
NKE

Hot Stocks

16:41 EDT Nike pares afterhours gains, down 0.9% after Q4 and FY23 outlook
STNG

Hot Stocks

16:39 EDT Scorpio Tankers in time charter-out agreement with total fixed revenue $43.8M - Scorpio Tankers announced that it has entered into a new time charter-out agreement of type LR2 - with Scrubber for three at a $ 40K daily tc rate with a total fixed revenue of $43.8M. The estimated time charter start is April 23.
QBTS

Hot Stocks

16:32 EDT D-Wave Quantum receives non-compliance notice from NYSE - D-Wave Quantum announced that it received notice from the New York Stock Exchange on March 16, 2023 that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because, as of March 15, 2023, the average closing price of the Company's common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company's common stock from the NYSE. On March 20, 2023, the Company notified the NYSE that it intends to cure the stock price deficiency and to return to compliance with the NYSE continued listing standard. The Company can regain compliance at any time within the six-month period following receipt of the NYSE notice if on the last trading day of any calendar month during the cure period the Company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under the NYSE's rules, if the Company determines that, if necessary, it will cure the stock price deficiency by taking an action that will require stockholder approval, it must so inform the NYSE in the above referenced notification and the price condition will be deemed cured if the price promptly exceeds $1.00 per share, and the price remains above that level for at least the following 30 trading days. The Company intends to consider available alternatives, including but not limited to a reverse stock split, that are subject to shareholder approval.
DRRX

Hot Stocks

16:31 EDT Durect names Gail Maderis as Chair of the Board - Durect announced that Gail Maderis has assumed the role of Chair of the Board, effective March 17. Maderis succeeds David Hoffmann as Chair of the Board. Hoffman has decided not to stand for re-election and will retire from the board on June 21 when his current term as a board member expires.
WAVD

Hot Stocks

16:25 EDT WaveDancer trading halted, news pending
BXC

Hot Stocks

16:21 EDT BlueLinx provides update on first 11 weeks of Q1 - Through the first 11 weeks of the first quarter of 2023, specialty product gross margin was in the range of 18% to 19%, with daily sales volumes lower by a range of 17% to 18% versus the prior year due to the current challenging macro environment and compared to a historically strong Q1 2022. Structural product gross margin was in the range of 10% to 11% with daily sales volumes relatively consistent when compared to last year. The company will continue to evaluate market pricing for wood-based commodities and adjust accordingly at the end of each period. The company intends to provide its full financial results for the first quarter 2023 in early May.
GME

Hot Stocks

16:18 EDT GameStop jumps nearly 33% to over $23 after reporting Q4 profit
NKE

Hot Stocks

16:18 EDT Nike jumps 4% to $131.00 after Q3 earnings beat
NKE

Hot Stocks

16:18 EDT Nike reports Q3-end inventories at $8.9B, up 16% from last year - The company states: "Inventories for NIKE, Inc. were $8.9B, up 16% compared to the prior year period, primarily driven by higher product input costs and elevated freight costs."
IFF

Hot Stocks

16:18 EDT IFF recommends stockholders reject mini-tender offer by TRC Capital - IFF has been notified that TRC Capital Investment Corporation has made an unsolicited "mini-tender offer" to purchase up to 1,500,000 shares of the Company's common stock, and, per a press release issued by TRC on March 20, has amended the terms of such offer to decrease the offer price payable from $89.95 to $81.60 per share in cash. TRC Capital Investment Corporation's offer price is approximately 1.4% lower than the $82.76 closing price of IFF's common stock on March 17, 2023, the last trading day prior to the date of the amended offer. IFF recommends that stockholders do not tender their shares in response to TRC's offer because the offer price is below the current market price of IFF's shares and is subject to numerous conditions, including TRC Capital Corporation obtaining financing for the offer. There is no guarantee the conditions of the offer will be satisfied. IFF recommends that stockholders who have not responded to TRC Capital Investment Corporation's offer take no action.
BXC

Hot Stocks

16:17 EDT BlueLinx board elects Shyam Reddy as CEO - BlueLinx announced that the board of directors has elected Shyam Reddy as president and CEO, effective immediately. In conjunction with his new role, he will also join the BlueLinx board of directors. Reddy succeeds Dwight A.K. Gibson, who is departing the company and stepping down as a member of the BlueLinx board. Reddy brings an understanding of BlueLinx's business and strategic opportunities to the role of CEO. He has served in a variety of positions over a nearly eight-year tenure at the company.
IFF

Hot Stocks

16:17 EDT IFF recommends stockholders reject mini-tender offer by TRC Capital - IFF shares of the company's common stock, and, per a press release issued by TRC on March 20, has amended the terms of such offer to decrease the offer price payable from $89.95 to $81.60 per share in cash. TRC Capital Investment Corporation's offer price is approximately 1.4% lower than the $82.76 closing price of IFF's common stock on March 17, 2023, the last trading day prior to the date of the amended offer. IFF recommends that stockholders do not tender their shares in response to TRC's offer because the offer price is below the current market price of IFF's shares and is subject to numerous conditions, including TRC Capital Corporation obtaining financing for the offer. There is no guarantee the conditions of the offer will be satisfied. IFF recommends that stockholders who have not responded to TRC Capital Investment Corporation's offer take no action. IFF stockholders who have already tendered their shares may withdraw them at any time by providing notice in the manner described in the TRC offering documents prior to the expiration of the offer, which is currently scheduled for 12:01 a.m. EDT on April 4, 2023, unless extended.
FG

Hot Stocks

16:16 EDT F&G Annuities announces $25M share repurchase program - F&G Annuities & Life announced that its Board of Directors has approved a new three-year stock repurchase program, effective March 21 under which the Company may repurchase up to $25M of FG common stock. Purchases may be made from time to time by the Company in the open market at prevailing market prices or in privately negotiated transactions through March 21, 2026. Chris Blunt, President and CEO, commented, "As we have executed on our business plan to double assets under management and earnings per share by expanding our business into new channels of distribution in advance of our original target timeframe, the market has been slow to recognize the value that has been created. As a result, our Board of Directors has authorized a $25M share repurchase program to take advantage of our shares currently trading at a significant discount to intrinsic value. Our share repurchase plan will complement our Board's recent $100M annual dividend authorization which, taken together, demonstrates our commitment to creating shareholder value through a healthy return of capital to our shareholders."
NKE

Hot Stocks

16:16 EDT Nike reports Direct sales up 17% at $5.3B - The company states: "NIKE Direct sales were $5.3 billion, up 17% on a reported basis and up 22% on a currency-neutral basis. NIKE Brand Digital sales increased 20% on a reported basis, or 24 percent on a currency-neutral basis. Wholesale revenues grew 12% on a reported basis and 18 percent on a currency-neutral basis. Gross margin decreased 330 basis points to 43.3%."
DOMH

Hot Stocks

16:16 EDT Dominari Holdings granted approval to acquire broker dealer - Dominari Holdings reported that on March 20, pursuant to FINRA Rule 1017, FINRA has approved the proposed change in ownership whereby its subsidiary Dominari Financial Inc. will become the sole owner of Fieldpoint Private Securities LLC. This matter is the next step in the previously announced agreement to buy Fieldpoint Private Securities. Final acquisition of the broker dealer is subject to a final closing, which by agreement among the parties, should occur within five business days of FINRA approval.
DBD

Hot Stocks

16:11 EDT Diebold confirms closing on $55M of additional liquidity - Diebold Nixdorf announced an amendment to its asset-based credit facility, or ABL, to add a new $55M first-in-last-out term loan tranche. Additionally, Diebold Nixdorf's ABL lenders have agreed to certain other modifications and waivers to the ABL facility, allowing them to continue to work together collaboratively to develop an updated borrowing framework. The existing $250 million non-FILO ABL tranche commitments remain in place. "Diebold Nixdorf recently disclosed in its annual 10-K that, despite a challenging macroeconomic environment, the company recorded $3.46 billion of revenue in 2022 and entered 2023 with a backlog of approximately $1.47 billion - demonstrating strong demand for its Banking and Retail solutions, specifically ATMs and self-checkout products. Also, the company recently released a brief financial update that shows the company is exhibiting strong performance and is on track to achieve its first quarter 2023 revenue target. ATM and SCO shipments are expected to increase in the first half of 2023 by approximately 14% and 51%, respectively, compared to the first half of last year. At this time, expected 2023 first quarter revenue of approximately $835 million would represent about 6% growth compared with the same period last year," the company stated. Octavio Marquez, Diebold Nixdorf chairman, president and CEO, said: "We are pleased to have secured the FILO loan to provide financing for our near-term priorities. We will continue to partner with our lenders to develop long-term improvements to our capital structure which will better support our operating model and the cycles of our business. We continue to take steps to improve our business by becoming more agile and better equipped to navigate global macroeconomic impacts. Our solution set is as robust as it ever has been, and we intend to accelerate our leadership in core areas to deliver profitable and sustainable growth."
SEE

Hot Stocks

16:10 EDT SEE names Dustin Semach CFO Designate - SEE announced that Dustin Semach will be joining the company as Chief Financial Officer Designate, effective April 17, 2023. He will succeed current CFO Christopher J. Stephens, Jr., who announced his intent to retire last year. To ensure a seamless transition of responsibilities, Chris will retire from the company following the filing of the Company's Quarterly Report on Form 10-Q for the first quarter 2023. "After a thorough internal and external search, we are excited that Dustin, with his unique background in both finance and digital technology, will be an important addition to the SEE team as we execute our Reinvent SEE 2.0, high-quality growth strategy," said Ted Doheny, President & CEO of SEE. "I look forward to Dustin quickly integrating into our team, accelerating our transformation into a world-class organization, and partnering with customers to deliver digital packaging solutions."
OLN

Hot Stocks

16:09 EDT Olin expects $57M in charges in Q1 due to closure of Cumene facility - Olin announced that it has made the decision to cease operations at its Cumene facility in Terneuzen, Netherlands and solid epoxy resin production at its facilities in Gumi, South Korea and Guaruja, Brazil. Olin's Q1 results are forecast to include approximately $57M of restructuring charges associated with these plans of which approximately $15M of these restructuring charges represent non-cash asset impairment charges. The cash component of these charges is expected to be paid over the next three years.
VMC CX

Hot Stocks

16:06 EDT Vulcan Materials issues statement regarding occupation of facilities in Mexico - Vulcan Materials (VMC) issued the following statement: "On Tuesday, March 14, 2023, CEMEX (CX), aided by armed Mexican police and military, forcibly entered Vulcan's port facilities near Playa del Carmen. They are still occupying the property. There is no contract permitting CEMEX's use of Vulcan's port facilities. Although the companies had an agreement for CEMEX to lease a portion of Vulcan's property, that agreement expired on December 31, 2022, without any renewal. Prior to the expiration, CEMEX was formally made aware that negotiation of a new contract would be necessary. Vulcan has been and remains open to renegotiating the lease agreement. Rather than looking for a mutually agreeable solution, CEMEX officers threatened to seek the aid of the Mexican government, including its armed forces, to use Vulcan's port facilities. On March 14 and to this day, CEMEX, the military and the police have not presented any court order, warrant or other legal justification for their forceful entry and occupation of Vulcan's property. Contrary to CEMEX's position, a Mexican federal court ordered CEMEX to vacate the property, and another Mexican federal court order requires military and police forces to leave the property immediately. The Mexican government continues its illegal shutdown of Vulcan's quarrying, processing and shipping operations. Nonetheless, Vulcan owns the four parcels of property that make up its Mexico operation, including the port facilities. Likewise, Vulcan lawfully holds the port concession. Use of Vulcan's private property by third parties, such as CEMEX, requires Vulcan's authorization."
PAYS

Hot Stocks

16:05 EDT Paysign announces new $5M stock buyback program - Paysign "announced that its Board of Directors has authorized a new stock repurchase program of up to $5,000,000 of the company's outstanding common stock, par value $0.001 per share. This program will commence immediately and is expected to be completed over the next 36 months."
BLUA

Hot Stocks

16:05 EDT BlueRiver Acquisition to complete transfer of listing to NYSE American - BlueRiver Acquisition announced that it was authorized to transfer its listing from the New York Stock Exchange to the NYSE American LLC. BlueRiver received written confirmation that it received the final approval for listing from the staff of NYSE American on March 21, 2023. In connection with the transfer, BlueRiver will voluntarily delist from the New York Stock Exchange, and expects to begin trading on the NYSE American on or about March 24, 2023.
SMLR

Hot Stocks

16:04 EDT Semler Scientific appoints Wayne Pan as CEO to succeed Doug Murphy-Chutorian - Semler Scientific announces that Doug Murphy-Chutorian, has informed the board of directors of his intention to step down from his position as CEO of Semler Scientific and assist for a transition period. He will continue to serve as a member of the board of directors at least through the remainder of his 2024 term. Semler Scientific's board of directors is pleased to announce the appointment of Wayne T. Pan as CEO to succeed Murphy-Chutorian. Pan's appointment as CEO will be effective from April 3, and Pan will remain a member of the board of directors. Pan has served as a member of Semler Scientific's board of directors since May 2014. Dr. Pan has over 20 years of broad healthcare industry experience from clinical medicine, to managed care, health information technology and biotechnology. Pan has over 20 years of broad healthcare industry experience from clinical medicine, to managed care, health information technology and biotechnology. Prior to his appointment as chief executive officer, from May 2022 through March 2023,Pan served as medical director at Banner Health, Insurance Division, responsible for all of Banner's Medicare Programs, including HMO, PPO and D-SNP. Prior to Banner, from June 2021 to May 2022, he was co-founder and chief medical officer of Salusive, a technology-enabled healthcare services company, based in Emeryville, CA, providing chronic care management and remote patient monitoring services to help physicians manage older adults with chronic conditions, leveraging a proprietary NLP/AI platform that enhances the effectiveness of clinical coaches in real-time as they connect with their patients.
COIN

Hot Stocks

15:01 EDT Coinbase strengthens commitment to Americas region with Brazil expansion - "We've integrated Pix for easy account top-up using Brazilian Reals, localized our app with 24/7 email support, partnered with Ebanx, and streamlined the user onboarding process. With our Country Director Fabio Plein expanding his role as Regional Managing Director, we aim to bring financial freedom to even more Brazilians through the cryptoeconomy and further strengthen our commitment to the Americas region....At Coinbase, we are dedicated to making it easy for anyone around the world to access the cryptoeconomy and enjoy financial freedom. You may read more about our approach to International Expansion and our 8-week International sprint here. Today, we are thrilled to announce some exciting updates for our customers in Brazil.First, we've made it simple for you to top up and withdraw money from your Coinbase account using Brazilian Real, thanks to our integration with Pix, a well-known instant payment platform created and managed by the Central Bank of Brazil," said the company, in part, on its blog. Reference Link
NWBO

Hot Stocks

14:49 EDT Northwest Biotherapeutics jumps 12% after approval for U.K. manufacturing - Shares of Northwest Biotherapeutics jumped 12% or 6c to 65c per share, after announcing, earlier on Tuesday, that it and contract developer, UK-based Advent BioServices, have been approved and issued by the Medicines and Healthcare Products Regulatory Agency MHRA for commercial manufacturing of cell therapy products at the GMP facility in Sawston, U.K...Linda Powers, CEO of NW Bio, commented, "We are very excited to reach this major milestone, as it is an essential step towards submission of our application for regulatory approval of our lead product, DCVax -L. It is especially exciting to be able to operate globally from this base in the U.K." Dr. Mike Scott, President of Advent BioServices, commented, "It is always challenging to be one of the trailblazers. The field of personalized cell-based immunotherapy is rapidly evolving and we are collectively navigating our way through the regulatory landscape. We are therefore thrilled that the extensive preparatory work undertaken by our skilled and dedicated team has met the extremely high standards set for this commercial level of manufacturing license."
BAYRY

Hot Stocks

14:16 EDT China's NMPA approves Bayer's Nubeqa for additional prostate cancer indication - The Chinese National Medical Products Administration or NMPA, has approved the oral androgen receptor inhibitor Nubeqa or darolutamide, in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer or mHSPC. Nubeqa is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer or nmCRPC, who are at high risk of developing metastatic disease. "Prostate cancer cases in China have increased significantly in recent years. Compounding that, nearly a third of patients who are newly diagnosed will have metastatic disease. We are therefore delighted that patients in China will now have a new treatment option for metastatic hormone-sensitive prostate cancer that delays disease progression, extends survival and maintains quality of life", said Christine Roth, Member of the Executive Committee of Bayer's Pharmaceuticals Division and Head of the Oncology SBU at Bayer. "Bayer is committed to improving health outcomes for people living with prostate cancerand that as many eligible patients as possible gain access to Nubeqa." Reference Link
NVDA

Hot Stocks

14:06 EDT Nvidia CEO says company has 'great relationship' with car companies - Says has "great relationship" with "basically every car company on the planet." Sees even greater demand from hyperscalers since last earnings report. Comments taken from GTC Financial Analyst Q&A.
NVDA

Hot Stocks

13:59 EDT Nvidia up 1% as company conducts analyst Q&A at GTC meeting - Shares of Nvidia are up $2.06, or 1%, to $261.06 in afternoon trading.
NVDA...

Hot Stocks

13:46 EDT Nvidia says Google Cloud integrating newly launched L4 GPU, Vertex AI - Nvidia (NVDA) announced Google Cloud (GOOGL) is integrating the newly launched L4 GPU and Vertex AI to "accelerate the work of companies building a rapidly expanding number of generative AI applications." Nvidia said: "Google Cloud, with its announcement of G2 virtual machines available in private preview today, is the first cloud services provider to offer NVIDIA's L4 Tensor Core GPU. Additionally, L4 GPUs will be available with optimized support on Vertex AI, which now supports building, tuning and deploying large generative AI models. Developers can access the latest state-of-the-art technology available to help them get new applications up and running quickly and cost-efficiently. The NVIDIA L4 GPU is a universal GPU for every workload, with enhanced AI video capabilities that can deliver 120x more AI-powered video performance than CPUs, combined with 99% better energy efficiency."
HSBC

Hot Stocks

13:44 EDT Texas Comptroller adds HSBC to energy sanctions list - Texas Comptroller Glenn Hegar announced yesterday that he has added a firm to his office's list of companies that boycott the oil and gas industry. HSBC Holdings Plc was added to the list following recent updates to the firm's energy policy. Listed companies are subject to the divestment provisions outlined in Texas Government Code Chapter 809, which define a financial company as a publicly traded financial services, banking or investment company. "This is significant given HSBC's status as Europe's largest bank, but it should not be surprising," Hegar said. "HSBC's new energy policy is a prime example of a broader movement in the financial sector to push a social agenda and prioritize political goals over the economic health of their clients. HSBC's policy clearly makes the firm a suitable candidate for listing under Texas law." The policy states "HSBC will not provide new finance or new advisory services to any client for the specific purposes of projects pertaining to new O&G fields where the final investment decision was taken after 31 Dec 2021 or infrastructure whose primary use is in conjunction with new O&G fields." Reference Link
INTC

Hot Stocks

13:33 EDT Intel appoints Stuart Pann as GM of Intel Foundry Services - Intel announced the appointment of Stuart Pann as senior vice president and general manager of Intel Foundry Services, or IFS, Intel's commercial foundry business. Pann will report to Intel CEO Pat Gelsinger and "drive continued growth for IFS and its differentiated systems foundry offering, which goes beyond traditional wafer fabrication to include packaging, chiplet standards and software, as well as U.S.- and Europe-based capacity," the company stated. Pann previously served as senior vice president, chief business transformation officer and general manager of Intel's Corporate Planning Group. "The industry is responding well to our systems foundry approach and we're seeing strong momentum, including the recent announcement of a significant cloud, edge and data center solutions provider as a customer for our upcoming Intel 3 process. With deep expertise in capital and capacity strategies, supply chain management, and sales and operations planning across internal and external manufacturing, Stuart is an ideal leader to accelerate this momentum and drive long-term growth for IFS," said Gelsinger.
ATOS

Hot Stocks

13:25 EDT Atossa says (Z)-endoxifen to be evaluated in new arm of ongoing I-SPY study - Atossa Therapeutics and Quantum Leap Healthcare Collaborative announce that Atossa's proprietary Selective Estrogen Receptor Modulator, or SERM, (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2 clinical trial. The I-SPY 2 TRIAL evaluates neoadjuvant treatments for locally advanced breast cancer and is a collaborative effort among academic investigators from major cancer research centers across the United States, Quantum Leap Healthcare Collaborative, the U.S. Food and Drug Administration, and the Foundation for the National Institutes of Health Cancer Biomarkers Consortium. Approximately 20 patients will be treated with (Z)-endoxifen for up to 24 weeks prior to surgery. Dr. Steven Quay, Atossa's President and CEO, said: "Data from this trial will supplement data generated through our ongoing Phase 2 EVANGELINE trial, which is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with ER+ / HER2- breast cancer. There remains a critical need for more effective and tolerable treatment options for this patient population."
LKCO

Hot Stocks

13:03 EDT Luokung Technology to implement 30-to-1 share combination - Luokung Technology reported that it expects to implement a 30-to-1 share combination on its ordinary shares effective Tuesday, March 22, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the ordinary shares will continue on the Nasdaq Capital Market under the symbol "LKCO".
BAOS

Hot Stocks

13:02 EDT Baosheng Media announces 6-to-1 share consolidation - Baosheng Media Group plans to effect a share consolidation of six ordinary shares with par value of $0.0016 per share each in the Company's issued and unissued share capital into one ordinary share with par value of $0.0096. As a result of the Share Consolidation, each six pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. The Share Consolidation will be effective on March 21, 2023. Beginning with the opening of trading on March 22, 2023, U.S. Eastern time, the Company's ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol "BAOS" but under a new CUSIP number of G08908 124. No fractional shares will be issued in connection with the Share Consolidation. All fractional shares will be rounded up to the whole number of shares. Immediately following the Share Consolidation, the authorized share capital of the Company will be $60,000 divided into 6,250,000 ordinary shares of par value of $0.0096 each.
YUM

Hot Stocks

13:01 EDT Yum! Brands COO Skeans sells $510K in company shares - The COO of Yum! Brands Tracy Skeans disclosed in a regulatory filing that she had sold 3,925 shares of company stock at $130 per share on March 27 for a total transaction amount of $510,250.
DYN

Hot Stocks

12:56 EDT Dyne Therapeutics granted orphan status for DMD treatment - The FDA granted Dyne Therapeutics orphan status for its treatment of Duchenne muscular dystrophy. Reference Link
NVS

Hot Stocks

12:56 EDT Novartis alpelisib granted FDA orphan designation - Novartis' alpelisib was granted FDA orphan designation as a treatment of lymphatic malformations, according to a post to the agency's website. Reference Link
OPHLY

Hot Stocks

12:54 EDT Ono Pharmaceutical's tirabrutinib granted FDA orphan designation - Ono Pharmaceutical's tirabrutinib was granted FDA orphan designation as a treatment of primary central nervous system lymphoma, according to a post to the agency's website. Reference Link
MRNS

Hot Stocks

12:53 EDT Marinus Pharmaceuticals ganaxolone granted FDA orphan designation - Marinus Pharmaceuticals ganaxolone was granted FDA orphan designation as a treatment of Lennox-Gastaut Syndrome, or LGS, according to a post to the agency's website. Reference Link
NVDA MSFT

Hot Stocks

12:24 EDT Nvidia says Nvidia Omniverse Cloud now available to select enterprises - NVIDIA (NVDA) announced that NVIDIA Omniverse Cloud, a platform-as-a-service that enables companies to unify digitalization across their core product and business processes, is now available to select enterprises. NVIDIA has selected Microsoft Azure (MSFT) as the first cloud service provider for Omniverse Cloud, giving enterprises access to the full-stack suite of Omniverse software applications and NVIDIA OVX infrastructure, with the scale and security of Azure cloud services.
SSTK NVDA

Hot Stocks

12:22 EDT Shutterstock, Nvidia partner to build AI foundation models - Shutterstock (SSTK) announced it is partnering with NVIDIA (NVDA) to train custom 3D models to create generative 3D assets from simple text prompts. Through a first of its kind collaboration, 3D models will be trained with Shutterstock assets using NVIDIA Picasso generative AI cloud services to convert text into high-fidelity 3D content, reducing creation time from hours to minutes. When the models are introduced in the coming months on Shutterstock.com, the new NVIDIA-powered generative AI capabilities will be the latest addition to Creative Flow, an extensive toolkit designed to power the most seamless creative experience possible. The text-to-3D features will also be offered on Turbosquid.com and is planned to be introduced on the NVIDIA Omniverse platform for building and operating 3D industrial metaverse applications.
TKR

Hot Stocks

12:21 EDT Timken sees Q1 earnings exceeding expectations - While the company didn't update guidance for Q1, Timken said the company previously expected Q1 revenue to be up mid- to high-single digits organically, but "We're now looking like we'll be up at least high single digits organically." Consensus is $1.23B. The company said its backlog remains healthy across most of the sectors it serves. The company expects Q1 earnings to exceed expectations and likely places it on a trajectory that would be towards the high end of guidance "if not higher." Comments taken from the BofA Global Industrials Conference.
NVDA BYDDF

Hot Stocks

12:20 EDT BYD to extend use of NVIDIA DRIVE Orin platform in broader range of NEVs - NVIDIA (NVDA) announced that BYD (BYDDF) will extend its use of the NVIDIA DRIVE Orin centralized compute platform in a broader range of its NEVs. The enhanced partnership expands BYD's use of DRIVE Orin across the multiple models in its next-generation Dynasty and Ocean series of vehicles, bringing safe and intelligent vehicles to market.
AMZN NVDA

Hot Stocks

12:18 EDT Amazon Web Services, Nvidia enter multi-part collaboration for AI infrastructure - Amazon Web Services (AMZN) and NVIDIA (NVDA) announced a multi-part collaboration focused on building out the world's most scalable, on-demand artificial intelligence infrastructure optimized for training increasingly complex large language models and developing generative AI applications. The joint work features next-generation Amazon Elastic Compute Cloud P5 instances powered by NVIDIA H100 Tensor Core GPUs and AWS's state-of-the-art networking and scalability that will deliver up to 20 exaFLOPS of compute performance for building and training the largest deep learning models. P5 instances will be the first GPU-based instance to take advantage of AWS's second-generation Elastic Fabric Adapter networking, which provides 3,200 Gbps of low-latency, high bandwidth networking throughput, enabling customers to scale up to 20,000 H100 GPUs in EC2 UltraClusters for on-demand access to supercomputer-class performance for AI.
NVDA ORCL

Hot Stocks

12:17 EDT Nvidia selects Oracle Cloud Infrastructure for AI services - Oracle (ORCL) has extended its collaboration with NVIDIA (NVDA) to include running strategic NVIDIA AI applications on the new Oracle Cloud Infrastructure Supercluster. NVIDIA has selected OCI as the first hyperscale cloud provider to offer NVIDIA DGX Cloud, an AI supercomputing service, at massive scale. In addition, NVIDIA is running NVIDIA AI Foundations, its new generative AI cloud services, which are available through DGX Cloud, on OCI. "OCI is the first platform to offer an AI supercomputer at scale to thousands of customers across every industry. This is a critical capability as more and more organizations require computing resources for their unique AI use cases. To support this demand, we continue to expand our work with NVIDIA," said Clay Magouyrk, executive vice president, Oracle Cloud Infrastructure.
NVDA

Hot Stocks

12:16 EDT Nvidia announces six new RTX Ada Lovelace architecture GPUs - NVIDIA announced six new NVIDIA RTX Ada Lovelace architecture GPUs for laptops and desktops. The company said: "Using the new NVIDIA RTX GPUs with NVIDIA Omniverse, a platform for building and operating metaverse applications, designers can simulate a concept before making it a reality, planners can visualize an entire factory before it is built and engineers can evaluate their designs in real time. The NVIDIA RTX 5000, RTX 4000, RTX 3500, RTX 3000 and RTX 2000 Ada Generation laptop GPUs deliver breakthrough performance and up to 2x the efficiency of the previous generation to tackle the most demanding workflows. For the desktop, the NVIDIA RTX 4000 Small Form Factor Ada Generation GPU features new RT Cores, Tensor Cores and CUDA cores with 20GB of graphics memory to deliver incredible performance in a compact card."
NVDA ADBE

Hot Stocks

12:02 EDT Nvidia, Adobe to co-develop new generation of advanced generative AI models - Adobe (ADBE) and NVIDIA (NVDA) announced a new partnership to unlock the power of generative AI to further advance creative workflows. Adobe and NVIDIA will co-develop a new generation of advanced generative AI models with a focus on deep integration into applications the world's leading creators and marketers use. Some of these models will be jointly developed and brought to market through Adobe's Creative Cloud flagship products like Adobe Photoshop, Adobe Premiere Pro, and Adobe After Effects, as well as through the new NVIDIA Picasso cloud service for broad reach to third-party developers. Priorities of the partnership include supporting commercial viability of the new technology and ensuring content transparency and Content Credentials powered by Adobe's Content Authenticity Initiative.
TME

Hot Stocks

12:00 EDT Tencent Music falls -10.0% - Tencent Music is down -10.0%, or -79c to $7.08.
NVDA...

Hot Stocks

12:00 EDT Nvidia announces availability of new products featuring H100 Tensor Core GPU - NVIDIA (NVDA) and key partners today announced the availability of new products and services featuring the NVIDIA H100 Tensor Core GPU to address rapidly growing demand for generative AI training and inference. Oracle Cloud Infrastructure (ORCL) announced the limited availability of new OCI Compute bare-metal GPU instances featuring H100 GPUs. Additionally, Amazon Web Services (AMZN) announced its forthcoming EC2 UltraClusters of Amazon EC2 P5 instances, which can scale in size up to 20,000 interconnected H100 GPUs. This follows Microsoft Azure's (MSFT) private preview announcement last week for its H100 virtual machine, ND H100 v5. Additionally, Meta (META) has now deployed its H100-powered Grand Teton AI supercomputer internally for its AI production and research teams.
HUYA

Hot Stocks

12:00 EDT Huya falls -15.1% - Huya is down -15.1%, or -59c to $3.33.
AG

Hot Stocks

12:00 EDT First Majestic falls -25.1% - First Majestic is down -25.1%, or -$1.86 to $5.58.
ONON

Hot Stocks

12:00 EDT On Holding rises 28.1% - On Holding is up 28.1%, or $6.06 to $27.63.
FRC

Hot Stocks

12:00 EDT First Republic rises 34.2% - First Republic is up 34.2%, or $4.16 to $16.34.
USX

Hot Stocks

12:00 EDT U.S. Xpress Enterprises rises 300.7% - U.S. Xpress Enterprises is up 300.7%, or $4.51 to $6.01.
NVDA AMGN

Hot Stocks

11:57 EDT Nvidia unveils language models, generative AI service to help Life Sciences R&D - Nvidia (NVDA) announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics. Part of Nvidia AI Foundations, the new BioNeMo Cloud service offering - for both AI model training and inference - accelerates the most time-consuming and costly stages of drug discovery. It enables researchers to fine-tune generative AI applications on their own proprietary data, and to run AI model inference directly in a web browser or through new cloud application programming interfaces that easily integrate into existing applications. Amgen (AMGN) is already using the service to advance its research and development efforts.
MSFT

Hot Stocks

11:53 EDT Microsoft says GPT-4 available in preview in Azure OpenAI Service - Microsoft said in a blog post that GPT-4 is available in preview in Azure OpenAI Service. Customers and partners already using Azure OpenAI Service can join the waitlist to access GPT-4 and start building with OpenAI's most advanced model yet. "With this milestone, we are proud to bring the world's most advanced AI models-including GPT-3.5, ChatGPT, and DALL*E 2-to Azure customers, backed by Azure AI-optimized infrastructure, enterprise-readiness, compliance, data security, and privacy controls, along with many integrations with other Azure services," said Eric Boyd, corporate VP of Microsoft's AI Platform.
NVDA...

Hot Stocks

11:42 EDT Nvidia announces new 'AI Foundations' services - Nvidia (NVDA) announced a set of cloud services that it said "enable businesses to build, refine and operate custom large language models and generative AI models that are trained with their own proprietary data and created for their unique domain-specific tasks." Getty Images (GETY), Morningstar (MORN), Quantiphi and Shutterstock (SSTK) are among the companies that will be creating and using AI models, applications and services being built with the new NVIDIA AI Foundations services that span language, images, video and 3D, Nvidia stated. "Enterprises can use the NVIDIA NeMo language service and the NVIDIA Picasso image, video and 3D service to build proprietary, domain-specific, generative AI applications for intelligent chat and customer support, professional content creation, digital simulation and more. Separately, NVIDIA today also announced new models for the NVIDIA BioNeMo cloud service for biology," the company added.
MSFT NVDA

Hot Stocks

11:38 EDT Nvidia announces industrial metaverse, AI collaboration with Microsoft - Nvidia (NVDA) announced a collaboration with Microsoft (MSFT) to provide hundreds of millions of Microsoft enterprise users with access to powerful industrial metaverse and AI supercomputing resources via the cloud. Microsoft Azure will host two new cloud offerings from Nvidia: Nvidia Omniverse Cloud, a platform-as-a-service giving instant access to a full-stack environment to design, develop, deploy and manage industrial metaverse applications; and Nvidia DGX Cloud, an AI supercomputing service that gives enterprises immediate access to the infrastructure and software needed to train advanced models for generative AI and other groundbreaking applications. Additionally, the companies are bringing together their productivity and 3D collaboration platforms by connecting Microsoft 365 applications - such as Teams, OneDrive and SharePoint - with Nvidia Omniverse, a platform for building and operating 3D industrial metaverse applications. The collaboration is expected to accelerate enterprises' ability to digitalize their operations, engage in the industrial metaverse and train advanced models for generative AI and other applications. With Omniverse connected to Azure Cloud Services Digital Twins and Internet of Things, companies can link real-time data from sensors in the physical world to their digital replicas. This will enable enterprises to build and operate more accurate, dynamic, fully functional 3D digital twins that automatically respond to changes in their physical environments. Azure provides the cloud infrastructure and capabilities needed to deploy enterprise services at scale, including security, identity and storage. A GTC keynote demo developed by Accenture amplifies the utility of integrating Nvidia Omniverse with Microsoft Teams to enable real-time 3D collaboration. Running on Omniverse Cloud, and leveraging a Teams Meeting featuring Live Share, the Accenture demo showcases how this integration can shorten the time between decision-making, action and feedback. Omniverse Cloud, powered by Nvidia OVX computing systems, will be available on Azure in the second half of the year. DGX Cloud will be available running in Azure beginning next quarter, providing enterprises with dedicated clusters of Nvidia DGX AI supercomputing and software, rented on a monthly basis.
NVDA

Hot Stocks

11:37 EDT Nvidia announces DGX Cloud 'AI supercomputing service ' - At GTC, Nvidia (NVDA) announced DGX Cloud, which it calls "an AI supercomputing service that gives enterprises immediate access to the infrastructure and software needed to train advanced models for generative AI and other groundbreaking applications." Nvidia said: "DGX Cloud provides dedicated clusters of NVIDIA DGX AI supercomputing, paired with NVIDIA AI software. The service makes it possible for every enterprise to access its own AI supercomputer using a simple web browser, removing the complexity of acquiring, deploying and managing on-premises infrastructure. Enterprises rent DGX Cloud clusters on a monthly basis, which ensures they can quickly and easily scale the development of large, multi-node training workloads without having to wait for accelerated computing resources that are often in high demand." "We are at the iPhone moment of AI. Startups are racing to build disruptive products and business models, and incumbents are looking to respond. DGX Cloud gives customers instant access to NVIDIA AI supercomputing in global-scale clouds.," added Jensen Huang, founder and CEO of NVIDIA.
ORCL NVDA

Hot Stocks

11:34 EDT Oracle's OCI adds Nvidia BlueField-3 DPU to networking stack - At GTC, Nvidia (NVDA) announced that Oracle Cloud Infrastructure, or OCI, has selected the NVIDIA BlueField-3 DPU as the latest addition to its networking stack, offering OCI customers "a powerful new option for offloading data center tasks from CPUs." Nvidia said: "BlueField-3 is NVIDIA's third-generation data processing unit that enables enterprises to build software-defined, hardware-accelerated IT infrastructures from cloud to data center to edge. It improves performance, efficiency and security in data centers by offloading, accelerating and isolating infrastructure workloads, thus freeing expensive CPU cores to run business applications. OCI offers a wide range of cloud infrastructure and platform services to its customers to build and run applications and services in the cloud or on premises. By utilizing BlueField-3, OCI is extending its long-established approach of offloading data center infrastructure tasks from CPUs."
NVDA...

Hot Stocks

11:28 EDT Nvidia says software library for computational lithography integrated by TSMC - At its GTC event, Nvidia (NVDA) announced what it calls "a breakthrough that brings accelerated computing to the field of computational lithography," enabling semiconductor leaders like ASML (ASML), TSMC (TSM) and Synopsys (SNPS) to accelerate the design and manufacturing of next-generation chips, just as current production processes are nearing the limits of what physics makes possible. "The new NVIDIA cuLitho software library for computational lithography is being integrated by TSMC, the world's leading foundry, as well as electronic design automation leader Synopsys into their software, manufacturing processes and systems for the latest-generation NVIDIA Hopper architecture GPUs. Equipment maker ASML is working closely with NVIDIA on GPUs and cuLitho, and is planning to integrate support for GPUs into all of its computational lithography software products. The advance will enable chips with tinier transistors and wires than is now achievable, while accelerating time to market and boosting energy efficiency of the massive data centers that run 24/7 to drive the manufacturing process," Nvidia said in a press release timed with the event.
NVDA MDT

Hot Stocks

11:27 EDT Medtronic, Nvidia collaborate to build AI platform for medical devices - Nvidia (NVDA) announced that it is collaborating with Medtronic (MDT) "to accelerate the development of AI in the healthcare system and bring new AI-based solutions into patient care." The companies will integrate Nvidia healthcare and edge AI technologies into Medtronic's GI Genius intelligent endoscopy module, developed and manufactured by Cosmo Pharmaceuticals. GI Genius is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer. GI Genius has been designed to host a suite of AI algorithms and integrating the Nvidia Clara healthcare platform could allow Medtronic to scale development of algorithms for real-time procedures, potentially accelerating AI innovation for better patient care. Medtronic intends to integrate Nvidia Holoscan - a real-time AI computing software platform for building medical devices - and Nvidia IGX, an industrial-grade edge AI hardware platform, to run with its GI Genius AI-assisted colonoscopy system to support physicians with AI-enhanced diagnostic images. Holoscan helps bring the latest AI applications into clinical settings by providing the full-stack infrastructure needed for scalable, software-defined processing of streaming data at the edge. The Nvidia Holoscan and IGX platform makes software-defined medical devices possible by enabling developers to efficiently train and validate AI models within the Cosmo Innovation Center, and then host the AI-powered applications on Medtronic's GI Genius AI Access Platform, a marketplace for software-as-a-medical-device applications. The first GI Genius systems built with the Nvidia technology will be available later this year.
CB CS

Hot Stocks

11:25 EDT Chubb says does not have exposure to any Credit Suisse AT1 bonds - In a regulatory filing, Chubb (CB) announced it does not have exposure to any Credit Suisse (CS) contingent convertible, or "CoCo/AT1," bonds in its investment portfolio holdings. "Chubb does not invest in contingent convertible, CoCo/AT1, bonds as part of its overall investment strategy. This disclosure is in response to recently published research reports that were incorrect," the company stated.
NVDA T

Hot Stocks

11:22 EDT Nvidia announces collaboration with AT&T - At its GTC event, Nvidia (NVDA) announced a collaboration in which AT&T (T) will "continue to transform its operations and enhance sustainability by using NVIDIA-powered AI for processing data, optimizing service-fleet routing and building digital avatars for employee support and training." Nvidia said: "AT&T is the first telecommunications provider to explore the use of a full suite of NVIDIA AI offerings. This includes enhancing its data processing using the NVIDIA AI Enterprise software suite, which includes the NVIDIA RAPIDS Accelerator for Apache Spark; enabling real-time vehicle routing and optimization with NVIDIA cuOpt; adopting digital avatars with NVIDIA Omniverse Avatar Cloud Engine and NVIDIA Tokkio; and utilizing conversational AI with NVIDIA Riva."
IONQ NVDA

Hot Stocks

11:20 EDT IonQ mentioned by Nvidia among partners integrating CUDA Quantum - Nvidia (NVDA) announced a new system built with Quantum Machines that it said "provides a revolutionary new architecture for researchers working in high-performance and low-latency quantum-classical computing." Nvidia said: "The world's first GPU-accelerated quantum computing system, the NVIDIA DGX Quantum brings together the world's most powerful accelerated computing platform - enabled by the NVIDIA Grace Hopper Superchip and CUDA Quantum open-source programming model - with the world's most advanced quantum control platform, OPX, by Quantum Machines." Nvidia also announced a new group of partners integrating CUDA Quantum into their platforms, including quantum hardware companies Anyon Systems, Atom Computing, IonQ (IONQ), ORCA Computing, Oxford Quantum Circuits, and QuEra; quantum software companies Agnostiq and QMware; and supercomputing centers National Institute of Advanced Industrial Science and Technology, the IT Center for Science, or CSC, and the National Center for Supercomputing Applications, or NCSA.
NVDA

Hot Stocks

11:16 EDT Nvidia announces new system for accelerated quantum-classical computing - NVIDIA announced a new system built with Quantum Machines that provides new architecture for researchers working in high-performance and low-latency quantum-classical computing. The company said: "The world's first GPU-accelerated quantum computing system, the NVIDIA DGX Quantum brings together the world's most powerful accelerated computing platform - enabled by the NVIDIA Grace Hopper Superchip and CUDA Quantum open-source programming model - with the world's most advanced quantum control platform, OPX, by Quantum Machines." "Quantum-accelerated supercomputing has the potential to reshape science and industry with capabilities that can serve humanity in enormous ways," said Tim Costa, director of HPC and quantum at NVIDIA. "NVIDIA DGX Quantum will enable researchers to push the boundaries of quantum-classical computing."
CVRX

Hot Stocks

11:06 EDT CVRx presents data from post-market phase of BeAT-HF trial - CVRx announced detailed preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure Therapeutics conference on Tuesday, March 21, 2023. These results are being presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina. Highlights of the data presented by Dr. Zile include: Safety - Major Adverse Neurological or Cardiovascular system or procedure-related event-free rate; MANCE-free rate of 97%; Long-term symptom improvement for Barostim Baroreflex Activation Therapy vs. Control: 6 Minute Hall Walk improved by 44 meters at 12 months; Quality of Life improved by 10 points in Minnesota Living with Heart Failure Questionnaire at 24 months; NYHA Class improved in 27% more BAT patients at 24 months; Mortality - primary endpoint; No statistically significant difference; All-cause mortality; 34% relative reduction in BAT vs. Control; Hierarchical composite of cardiovascular death, LVAD, heart transplant, HF hospitalization, and Quality of Life using Win Ratio; Win Ratio of 1.26 favored BAT vs. Control. Dr. Zile's presentation concludes that the "Totality of evidence indicates that BAT is a safe, effective and durable treatment for patients with heart failure with reduced ejection fraction." The full results of BeAT-HF, including a number of additional analyses and endpoints, will be submitted by the executive steering committee for publication in one or more peer-reviewed journals. CVRx anticipates that regulatory submission to the FDA for expanded labeling will be made in the coming months.
NVS

Hot Stocks

10:51 EDT Novartis' Sandoz receives FDA approval for biosimilar Hyrimoz HCF - Sandoz, a Novartis division, announced that the U.S. Food and Drug Administration approved a citrate-free high-concentration formulation of its biosimilar Hyrimoz injection. The adalimumab citrate-free HCF 100 mg/mL is approved to treat seven indications covered by the reference medicine, Humira, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis. Sandoz intends to launch the Hyrimoz citrate-free HCF in the U.S. on July 1, the company stated.
RHI

Hot Stocks

10:47 EDT Robert Half appoints JoLynn Conway-James to CAO - Robert Half has promoted JoLynn Conway-James to senior executive director and chief administrative officer, overseeing the company's operational administration and global human resources teams. Conway-James' career at Robert Half spans more than three decades. She has held key leadership positions, including vice president of field support, executive director of executive committee affairs and staffing administration, and, most recently, senior vice president of operational support.
LUV SABR

Hot Stocks

10:39 EDT Southwest expands partnership with Sabre for PRISM - Southwest Airlines Co. (LUV) announced an expanded partnership with Sabre Corporation to begin utilizing PRISM, an data solution designed to streamline the sales process with corporate travel managers and travel management companies. Sabre's PRISM brings decision science to the Southwest(R)Business Sales Team, allowing the ability to develop a more customized travel solution for business Customers through automated, real-time data insights and trends.
PRPO

Hot Stocks

10:31 EDT Precipio ships first IV-Cell order to U.S. healthcare system - Precipio delivered its first order of IV-Cell, the company's proprietary cytogenetics cell culturing media, to a major U.S. healthcare system. The healthcare system has successfully completed the validation of the media and will begin the gradual incorporation into clinical use, Precipio said in a statement.
CBRE

Hot Stocks

10:03 EDT Akima, CBRE awarded IDIQ contract by GSA for electric vehicle charging - Akima Intra-Data and its partner CBRE announced the award of a design/build and construction Indefinite Delivery Indefinite Quantity contract by the GSA to support Electric Vehicle Supply Equipment installation and related infrastructure improvements.
FRC

Hot Stocks

10:03 EDT First Republic trading resumes
NYMX

Hot Stocks

10:02 EDT Nymox announces appointment of Christopher Riley as CFO - Nymox Pharmaceutical announced the appointment of Christopher R. Riley as CFO of Nymox. Riley was CFO for Frito-Lay Australia where he was in charge of the snack food division, and during his tenure he was key executive responsible for the re-engineering of its distribution system. Paul Averback, President & CEO of Nymox stated, "We are extremely pleased to welcome Chris as part of our management team. He has experience with small as well as large companies, has a science background, and he is very familiar with Nymox's structure and the Company's potential. Chris is a seasoned pro with the kind of real world business experience and qualifications that make him very much the CFO that our shareholders expect for this important position moving forward with Nymox."
FAZ

Hot Stocks

10:00 EDT Direxion Financial Bear 3x falls -8.2% - Direxion Financial Bear 3x is down -8.2%, or -$2.00 to $22.51.
HUYA

Hot Stocks

10:00 EDT Huya falls -12.5% - Huya is down -12.5%, or -49c to $3.43.
AG

Hot Stocks

10:00 EDT First Majestic falls -19.3% - First Majestic is down -19.3%, or -$1.44 to $6.00.
ONON

Hot Stocks

10:00 EDT On Holding rises 24.1% - On Holding is up 24.1%, or $5.20 to $26.77.
FRC

Hot Stocks

10:00 EDT First Republic rises 25.7% - First Republic is up 25.7%, or $3.12 to $15.30.
USX

Hot Stocks

10:00 EDT U.S. Xpress Enterprises rises 294.3% - U.S. Xpress Enterprises is up 294.3%, or $4.42 to $5.92.
FRC

Hot Stocks

09:57 EDT First Republic trading halted, volatility trading pause
ZEST...

Hot Stocks

09:52 EDT Ecoark Holdings changes name to BitNile Metaverse - BitNile Metaverse announced that the Company has changed its name from Ecoark Holdings to BitNile Metaversw to reflect its focus on growing its browser-based metaverse solution as its core business. The Company's shares will continue to be traded on The Nasdaq Capital Market. The Company's ticker symbol will change from "ZEST" to "BNMV". The name and stock ticker are the next steps after the Company's recent acquisition of BitNile.com, Inc. from Ault Alliance, Inc. (AULT).
NRAC

Hot Stocks

09:50 EDT Noble Rock Acquisition Corp trading resumes
FAZ

Hot Stocks

09:47 EDT Direxion Financial Bear 3x falls -8.0% - Direxion Financial Bear 3x is down -8.0%, or -$1.96 to $22.55.
HUYA

Hot Stocks

09:47 EDT Huya falls -8.4% - Huya is down -8.4%, or -33c to $3.59.
AG

Hot Stocks

09:47 EDT First Majestic falls -17.2% - First Majestic is down -17.2%, or -$1.28 to $6.16.
ONON

Hot Stocks

09:47 EDT On Holding rises 22.9% - On Holding is up 22.9%, or $4.95 to $26.52.
FRC

Hot Stocks

09:47 EDT First Republic rises 27.3% - First Republic is up 27.3%, or $3.32 to $15.50.
USX

Hot Stocks

09:47 EDT U.S. Xpress Enterprises rises 294.7% - U.S. Xpress Enterprises is up 294.7%, or $4.42 to $5.92.
KSCP

Hot Stocks

09:41 EDT Knightscope announces three orders for K1 emergency communication products - Knightscope announced three new orders for its K1 emergency communication suite of products. A New Hampshire university purchased its first Knightscope K1 Retrofit Kit to test in anticipation of a larger roll out; the Borough of Carteret Police Department in New Jersey bought 2 K1 Blue Light Towers for a local park; and the Port Authority NY NJ expanded their previous order to include an additional 6 K1 Call Boxes for the Bayonne Bridge.
GILD

Hot Stocks

09:40 EDT Kite announces primary OS analysis results of Phase 3 ZUMA-7 study - Kite announced the primary overall survival analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma within 12 months of completion of first-line therapy. Historical SOC is a multi-step process involving platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy and stem cell transplant in those who respond to salvage chemotherapy. These findings will be presented in full later this year at an upcoming scientific meeting. OS was designated as a clinically important prespecified key secondary endpoint, defined as the length of time from randomization to death from any cause. ZUMA-7 was conducted under a Special Protocol Assessment with the U.S. Food and Drug Administration whereby the trial design, clinical endpoints and statistical analysis were agreed upon in advance with the Agency. This pre-specified analysis was also agreed by other health authorities. ZUMA-7 is considered a landmark trial as the first and largest Phase 3 study of any CAR T-cell therapy, with the longest follow-up, which has demonstrated event-free survival, the primary endpoint, that is superior to historical SOC treatment. Data from the ZUMA-7 pivotal trial led to the U.S. approval for initial treatment of R/R LBCL in April 2022 and European Union approval in October 2022, followed by approvals in a number of other countries such as: Great Britain, Israel, Japan, and Switzerland.
HCDI

Hot Stocks

09:32 EDT Harbor Custom Development regains Nasdaq compliance - Harbor Custom Development has regained compliance with the continued listing standards of the Nasdaq Capital Market. On March 20, 2023, Harbor received written notice from Nasdaq that the closing bid price of its common stock trading under the symbol "HCDI" has been at $1.00 per share or greater for the ten consecutive trading days for the period of March 6, 2023, to March 17, 2023, and as a result has regained compliance with Listing Rule 5550(a)(2). The previously announced notice of potential delisting has now been closed.
LBTYA LBTYK

Hot Stocks

09:29 EDT Liberty Global to launch takeover bid of EUR 22 per share for Telenet unit - Liberty Global announces that, through its wholly-owned subsidiary Liberty Global Belgium Holding it intends to launch a voluntary and conditional public takeover bid for all the shares of Telenet Group Holding that it does not already own or that are not held by Telenet . Liberty Global has been the controlling shareholder of Telenet since February 2007 and currently owns 59.18% of Telenet's outstanding issued share capital. Telenet owns 3.12% of the outstanding issued share capital in treasury. The Intended Offer would be an offer in cash at a price of EUR 22.00 per share. This price represents a premium of 59% compared to the closing price of Telenet on March 15, 2023, and a premium of 52% compared to the volume-weighted average trading price of Telenet over one month before such date. Telenet's board of directors, subject to customary conditions, unanimously supports and recommends the Intended Offer as confirmed in the statement Telenet has issued today. The Telenet board of directors will provide its formal opinion in a response memorandum which it will issue in accordance with the applicable legal framework. If Telenet's ordinary general meeting on 26 April 2023 approves the payment of a gross dividend of EUR 1.00 per share as proposed by Telenet's board of directors and the ex-dividend date falls prior to the date of payment of the offer price, the offer price per share will be reduced by the total gross amount of such dividend (before any applicable tax deduction). Mike Fries, CEO, Liberty Global, commented: "We believe an offer of EUR 22.00 per share provides a good opportunity for Telenet shareholders to monetize their investment at an attractive premium. We welcome the unanimous decision of Telenet's board of directors to support and recommend this offer. We are proud of how Telenet has evolved in recent years, and we are fully committed to Belgium and all the company's stakeholders." The purchase of shares will be funded by non-recourse debt financing obtained by Liberty Global Belgium Holding. No Liberty Global corporate cash, liquidity or corporate guarantees are required to finance the share purchases.
IVDA

Hot Stocks

09:29 EDT Iveda Philippines targets a minimum of $3M in initial deployments for 2023 - Iveda announces an update following the October launch of Iveda Philippines JV, anticipating initial 2023 deployments to be a minimum of $3M. Each initial smart city deployment across the region will range from $250,000 to $500,000 with recurring revenue for annual fees covering software maintenance and upgrades.
MTEK

Hot Stocks

09:28 EDT Maris-Tech enters collaboration agreement with Art of Logic - Maris-Tech announced the signing of a collaboration agreement with Art of Logic, an Australian company, leveraging the latest computer vision and machine learning to enable smart solutions to solve critical business outcomes. The collaboration agreement focuses on enhanced technology combining, which will allow Maris- Tech to offer AI applications on its Maris-Edge platforms in addition to its intelligent video transmission technology. AOL will be appointed as Maris- Tech exclusive representative in Australia and New Zealand, subject to the entry into a definitive agreement, and granted non-exclusive worldwide license to rebrand, promote and resell the products it purchases from Maris-Tech. In addition, AOL's wide presence in Australia and New Zealand will enable Maris- Tech to offer its AI and video based solutions to companies in the defense, space and Home Land Security sectors. AOL will also develop Maris- Tech' customer's AI applications and will provide support to Maris-Tech's customers, which intend to develop their own applications of the Hailo AI accelerator or had already-developed AI applications, from a certain AI accelerators to the Hailo accelerator.
LSDI

Hot Stocks

09:24 EDT Lucy Scientific Discovery to acquire SANA-013 assets from Wesana Health - Lucy Scientific Discovery entered into a definitive asset purchase agreement with Wesana Health Holdings. Lucy has agreed to acquire intellectual property and related assets for Wesana's psilocybin and cannabidiol combination investigational therapy, SANA-013, and Wesana's supply of psilocybin which is sufficient to complete all near-term clinical studies. The aggregate consideration comprises 1,000,000 shares of common stock and $570,000 in cash. The shares will be subject to a lock-up agreement whereby half of the shares will be released 9 months from closing, and other half will be released 14 months from closing. The transaction is also subject to Wesana's shareholder approval and is expected to close in Q2 2023. As a result of this acquisition, Lucy will add drug development capabilities to its existing business of psychedelics manufacturing. SANA-013 is a proprietary combination of psilocybin and CBD being developed for the potential treatment of several mental health/CNS-related conditions, including Major Depressive Disorder, Migraine, Episodic Cluster Headaches, and Trigeminal Neuralgia. This novel combination allows both drugs to act within the brain via complementary pathways. Specifically, SANA-013 is thought to work, by "rewiring" neuron connections in the brain while also inducing a potent anti-inflammatory effect that, together, lead to anti-depressant effects. As part of the transaction, Wesana's CEO, Dan Carcillo, will join Lucy's executive team to help guide the continued development of SANA-013 into first human testing, expected to commence in late 2023.
WSNAF

Hot Stocks

09:22 EDT Wesana Health CFO Zed Wang resigns, Winfield Ding to succeed - Wesana also announces that as part of a planned transition, Mr. Zed Wang has resigned as the Company's Chief Financial Officer and Corporate Secretary, and Mr. Winfield Ding has been appointed as the Company's Chief Financial Officer and Corporate Secretary, effective immediately. Mr. Wang will be remain available to ensure a smooth transition.A former audit manager and currently a self-practitioner Ding has worked in audit, taxation and advisory roles across a wide range of industries with a focus on public issuers financial reporting and business advisory.
NNDM

Hot Stocks

09:19 EDT Nano Dimension responds to Murchinson claims about shareholder meeting results - Nano Dimension said, "From the start, Murchinson's campaign has been predicated on falsehoods, misinformation and bad-faith actions. The announcement yesterday is merely a continuation of efforts to deceive shareholders by claiming 'victory' in a meeting that had no validity and therefore was of no consequence. Excluding shares owned by Murchinson and Anson - who we have strong reason to believe has been acting in concert with Murchinson - the campaign received support from less than 9.5% of shares voted. Put another way, more than 90% of the Company's shares voted that are unaffiliated with Murchinson and Anson either voted against Murchinson's proposed nominees or opted not to participate in this fraudulent vote. The low voter turnout, which was less than 13% of shares as of the record date excluding Murchinson and Anson owned shares, and lack of support for Murchinson's nominees demonstrates that our shareholders will not be coerced by an actor who the Company believes is solely interested in making a quick profit at the expense of substantial potential long-term value for other shareholders. It further highlights the inherent flaws in Murchinson's intense yet selective solicitation effort. This invalid and partial process and subsequent outcome is precisely what the Company's Board of Directors warned against and wanted to avoid in order to protect the voice of ALL shareholders." Nano Dimension shareholders should disregard any voting results released by Murchinson. The meeting - and therefore the vote - is invalid.
NRAC

Hot Stocks

09:18 EDT Braiin to go public through Northern Revival Acquisition combination - Northern Revival Acquisition Corporation, a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, or similar business combination with one or more businesses, announced that it has entered into a business combination agreement with Braiin. Under the BCA, NRAC will acquire all the outstanding shares of Braiin from its existing shareholders in exchange for newly issued ordinary shares of NRAC. Braiin shareholders holding 100% of its currently outstanding ordinary shares have signed on to sell their shares to NRAC under the BCA. Prior to closing, all convertible securities of Braiin will be converted into Braiin ordinary shares, which will also be exchanged for NRAC ordinary shares. The pro forma value of the combined company is expected to be approximately $215M. Upon the closing, current Braiin shareholders will retain 100% of their equity through new ordinary shares of NRAC and will own approximately 65% of the post-closing combined public company, assuming no redemptions by NRAC's public shareholders. The transaction is expected to close in Q2 or Q3 of 2023 and is subject to approval by NRAC's shareholders and other customary closing conditions.
ATOS

Hot Stocks

09:18 EDT Atossa, Quantum Leap announce new study arm to evaluate z-Endoxifen - Atossa Therapeutics and Quantum Leap Healthcare Collaborative announce that Atossa's proprietary Selective Estrogen Receptor Modulator, SERM, (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2 clinical trial. The I-SPY 2 TRIAL evaluates neoadjuvant treatments for locally advanced breast cancer and is a collaborative effort among academic investigators from major cancer research centers across the United States, Quantum Leap Healthcare Collaborative, the U.S. Food and Drug Administration, and the Foundation for the National Institutes of Health, FNIH, Cancer Biomarkers Consortium. The new study arm evaluating (Z)-endoxifen is part of the ongoing I-SPY 2 Endocrine Optimization Pilot Protocol, which targets patients with newly diagnosed estrogen receptor-positive invasive breast cancer whose tumors are predicted to be sensitive to endocrine therapy but for whom chemotherapy is expected to provide little or no benefit. Atossa is currently evaluating (Z)-endoxifen in two ongoing Phase 2 studies: The EVANGELINE trial is a randomized non-inferiority study of (Z)-endoxifen compared to exemestane plus goserelin as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 ER+ / HER2- breast cancer. The Karisma-Endoxifen trial is a randomized, double-blind, placebo-controlled efficacy study of oral (Z)-endoxifen in premenopausal women with measurable breast density.
CXDO

Hot Stocks

09:17 EDT Crexendo appoints Gateway to lead expanded IR program - Crexendo has appointed Gateway Investor Relations to manage its expanded investor relations program initiatives, including providing corporate messaging and other consulting services to the Company.
LSDI WSNAF

Hot Stocks

09:15 EDT Wesana Health announces sale of SANA-13 asset to Lucy Scientific - Wesana Health (WSNAF) announced that the Company has entered into a definitive asset purchase agreement dated March 20 2023 with Lucy Scientific Discovery (LSDI) for the sale by Wesana Health, a subsidiary of the Company, of its SANA-013 intellectual property and related assets for consideration of 1,000,000 common shares of Lucy and US$570,000 in cash. Pursuant to the Asset Purchase Agreement, Lucy, an arms-length party to the Company, has agreed to acquire WHI's SANA-013 intellectual property and related assets for aggregate consideration comprised of the Share Consideration and the Cash Consideration, as outlined in the Asset Purchase Agreement. US$300,000 of the Cash Consideration is anticipated to be paid to WHI shortly and the remainder of the Cash Consideration is required to be paid to WHI at closing. The proceeds from the Transaction are to be used by WHI for reasonable general corporate purposes which WHI deems necessary in its sole discretion to the development of SANA-013 and/or completion of the transaction contemplated by the Asset Purchase Agreement. The Share Consideration shall be subject to a lock-up agreement. The Share Consideration will be issued as "restricted securities" under the United States Securities Act of 1933, as amended, and may be publicly resold, subject to terms of the Lock-Up Agreement, in compliance with Rule 144 thereunder. The Asset Purchase Agreement also contains customary non-solicitation covenants on the part of Wesana with respect to alternative transactions. Among other conditions precedent, the consummation of the Transaction is subject to the approval of at least 66 2/3% of the votes cast by Wesana shareholders voting in person or represented by proxy at a meeting of Wesana shareholders to be called by Wesana for purposes of considering the Transaction. The Transaction is expected to close in the second quarter of 2023, subject to and following the satisfaction of the conditions precedent to the Transaction. Subject to agreement on terms, it is anticipated that Wesana's CEO and Chairman Daniel Carcillo will join Lucy's team to integrate SANA-013 within Lucy. Wesana also announces that as part of a planned transition, Zed Wang has resigned as the Company's Chief Financial Officer and Corporate Secretary, and Winfield Ding has been appointed as the Company's Chief Financial Officer and Corporate Secretary, effective immediately. The Company's board of directors, after receiving a recommendation from a special committee of the Board, has determined that the Transaction is in the best interests of the Company and that the consideration to be received by the Company pursuant to the Transaction is fair to the Company.
NAOV

Hot Stocks

09:15 EDT NanoVibronix spikes 6% higher in pre-market after announcing patent application
WSNAF

Hot Stocks

09:14 EDT Wesana Health CFO Zed Wang resigns, Winfield Ding to succeed - Wesana announces that as part of a planned transition, Mr. Zed Wang has resigned as the Company's CFO and Corporate Secretary, and Mr. Winfield Ding has been appointed as the Company's CFO and Corporate Secretary, effective immediately. Mr. Wang will be remain available to ensure a smooth transition. A former audit manager and currently a self-practitioner, Ding has worked in audit, taxation and advisory roles across a wide range of industries with a focus on public issuers financial reporting and business advisory.
USX

Hot Stocks

09:14 EDT US Xpress Enterprises trading resumes
TMUS

Hot Stocks

09:13 EDT T-Mobile selected by AAA as 'exclusive wireless partner' in 'long term' pact - T-Mobile announced that AAA has selected the Un-carrier to be its exclusive wireless partner to help keep their drivers and members safe when minutes count. Under this long-term agreement, T-Mobile will provide connectivity for AAA-owned roadside assistance fleets nationwide. Additionally, T-Mobile has outfitted thousands of AAA roadside assistance technicians with 5G phones so they can stay connected on the road and beyond. One of North America's largest and most trusted membership organizations, AAA serves more than 63 million members and responds to approximately 30 million calls for roadside assistance annually. And moments matter for the safety of tow providers, emergency responders and travelers who are on the side of today's busy and congested roads. Every minute a person is stopped on a freeway, the risk of being seriously injured or killed in a secondary crash increases. In fact, according to the Federal Highway Administration, the likelihood of a secondary crash goes up by 2.8 percent for each minute the primary accident continues to be a hazard. So, to help reduce time spent at the side of the road, AAA will rely on the 5G network that covers more US highway miles than any other carrier.
WSNAF LSDI

Hot Stocks

09:13 EDT Wesana Health CEO Daniel Carcillo to join Lucy Scientific Discovery - Subject to agreement on terms, it is anticipated that Wesana's CEO and Chairman Daniel Carcillo will join Lucy's team to integrate SANA-013 within Lucy.
WSNAF LSDI

Hot Stocks

09:12 EDT Wesana Health sells SANA-13 assets to Lucy Scientific Discovery - Wesana Health (WSNAF) entered into a definitive asset purchase agreement dated March 20 2023 with Lucy Scientific Discovery (LSDI) and related assets for consideration of 1,000,000 common shares of Lucy and $570,000 in cash. Transaction Highlights: The Transaction provides an opportunity for the continued development of SANA-013 through the next phases of the US FDA regulatory process and for the Company to have economic exposure to any positive advancements in any such future research and development efforts by Lucy. The Company will also have economic exposure to the broader Lucy asset portfolio and pipeline, including a Canadian Licensed Dealer conducting research on various compounds. The Transaction is expected to close in Q2 2023, subject to and following the satisfaction of the conditions precedent to the Transaction. Pursuant to the Asset Purchase Agreement, Lucy, an arms-length party to the Company, has agreed to acquire WHI's SANA-013 intellectual property and related assets for aggregate consideration comprised of the Share Consideration and the Cash Consideration, as outlined in the Asset Purchase Agreement. $300,000 of the Cash Consideration is anticipated to be paid to WHI shortly and the remainder of the Cash Consideration is required to be paid to WHI at closing. The proceeds from the Transaction are to be used by WHI for reasonable general corporate purposes which WHI deems necessary in its sole discretion to the development of SANA-013 and/or completion of the transaction contemplated by the Asset Purchase Agreement. The Share Consideration shall be subject to a lock-up agreement whereby one-half of the Share Consideration will be released 9 months from initial trading date of LSDI shares, and one-half of the Share Consideration will be released 14 months from the initial trading date of LSDI shares. The Share Consideration will be issued as "restricted securities" under the United States Securities Act of 1933, as amended, and may be publicly resold, subject to terms of the Lock-Up Agreement, in compliance with Rule 144 thereunder. Lucy has granted the Company demand registration rights in the event that Rule 144 is not available for the public resale of the Share Consideration, and piggy-back registration rights. The Asset Purchase Agreement also contains customary non-solicitation covenants on the part of Wesana with respect to alternative transactions. Among other conditions precedent, the consummation of the Transaction is subject to the approval of at least 66 2/3% of the votes cast by Wesana shareholders voting in person or represented by proxy at a meeting of Wesana shareholders to be called by Wesana for purposes of considering the Transaction. Certain shareholders of Wesana, representing all of the outstanding Wesana super voting shares, 23.1% of the outstanding Wesana proportionate subordinate voting shares and 14.7% of the outstanding Wesana subordinate voting shares, have entered into support agreements with Wesana, agreeing to support the Transaction and vote their Wesana shares in favour of the Transaction at the shareholders meeting to be called by Wesana for purposes of considering the Transaction.
CMI

Hot Stocks

09:10 EDT Cummins opens Atlanta satellite office and Tech Hub called CAH - Cummins unveiled its new office location, the Cummins Atlanta Hub, CAH, located in Atlanta, Georgia. The Hub will continue supporting the future success and growth of Cummins, initially serving as the home for the supply chain planning group and members of the information technology team, with more groups to follow in the future. The new project is a direct reflection of Cummins' commitment to powering a more prosperous world through improving communities in which it operates to have a direct impact on the lives of its employees and its neighbors. "For Cummins to be successful, we need to attract, build and retain the best talent to solve the challenges our customers and communities face today and tomorrow and create inclusive environments where our people and innovation thrive," said Cummins President and Chief Executive Officer, Jennifer Rumsey. "The opening of an office in Atlanta is a clear reflection of Cummins' continued investments and efforts in our current and future employees and communities."
KNX USX

Hot Stocks

09:10 EDT Knight-Swift to acquire U.S. Xpress Enterprises for $6.15 per share - Knight-Swift (KNX) and U.S. Xpress Enterprises (USX) announced an agreement under which Knight-Swift will acquire U.S. Xpress for a total enterprise value of approximately $808M, excluding transaction costs. The transaction has been unanimously approved by the board of directors of Knight-Swift and a special committee of the independent directors of the U.S. Xpress board of directors. It is expected to close late in the second quarter or early third quarter of 2023, subject to customary closing conditions. In the transaction, U.S. Xpress stockholders will receive $6.15 per share in cash for each outstanding share of U.S. Xpress Class A and Class B common stock, except Max Fuller, executive chairman of U.S. Xpress, and Eric Fuller and related entities will rollover a portion of their shares of U.S. Xpress into an approximately 10% interest in a new Knight-Swift subsidiary formed to hold the U.S. Xpress business post-closing. The rollover interests will be subject to optional and mandatory redemption provisions based on the future performance of the U.S. Xpress business post-closing. As minority owners in the future U.S. Xpress, the Fullers have agreed to certain restrictive covenants. The total enterprise value of $808M for U.S. Xpress represents Knight-Swift assuming U.S. Xpress' $484 million of outstanding debt and finance leases and purchasing its outstanding equity for $324 million, or $6.15 per share, and excludes its $336 million of operating lease liabilities for the purposes of this calculation. As of December 31, 2022, U.S. Xpress had approximately $96M in outstanding borrowings under its secured revolving credit facility and $388 million in other long-term debt and finance leases. Knight-Swift expects to repay and terminate the U.S. Xpress secured revolving credit facility at closing while seeking to retain in place U.S. Xpress' existing primarily fixed-rate equipment and real estate financing arrangements. Knight-Swift had approximately $1.3B unrestricted cash and available liquidity on December 31, 2022, a portion of which will fund the transaction.
REG

Hot Stocks

09:10 EDT Regency Centers announces leadership promotions, expanded roles - Regency Centers Corporation announced the following leadership promotions, effective as of March 13, 2023. Barry Argalas is now Managing Director, Transactions. He brings 27 years of experience at Regency. Terah Devereaux is now Senior Vice President, Chief Accounting Officer. She brings over 23 years of accounting experience, including 18 years with Regency, most recently in her position as Senior Vice President of Accounting and Reporting. Patrick McKinley is now Senior Vice President, Senior Market Officer. Patrick has been a key member of Regency's Florida team for nearly 18 years. Abe Pacetti is now Senior Vice President, Investments - Texas. His experience encompasses over 25 years at the Company, including a decade as an officer in investments strategy.
USX KNX

Hot Stocks

09:08 EDT Knight-Swift to acquire U.S. Xpress Enterprises for $6.15 per share
SCLX

Hot Stocks

09:08 EDT Scilex announces financing of up to $25M to enhance commercialization - Scilex Holding, a majority-owned subsidiary of Sorrento Therapeutics, announced that it has entered into a securities purchase agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global, for the issuance and sale of unsecured convertible debentures in the principal amount of up to $25 million. The convertible debentures will be issued and sold in three tranches as follows: $10.0 million upon the signing of the definitive agreement with respect to the debentures, $7.5 million upon the filing of a registration statement with the U.S. Securities and Exchange Commission relating to the shares of common stock underlying the convertible debentures, and $7.5 million at the time such registration statement is declared effective by the SEC. The convertible debentures will bear interest at a rate of 7.00% per year and will mature on December 21, 2023, the date that is nine months following the First Closing Date. Scilex intends to use the proceeds to enhance the commercialization of Scilex's three non-opioid pain management products for the treatment of acute and chronic pain. "We are pleased to conclude this agreement with Yorkville, which will provide funding to expand ZTlido promotion worldwide and enhance the launch and commercialization of Gloperba and ELYXYB. We believe the acute and chronic pain patients are not well served with the current options on the market. A recent report from the Centers for Disease Control and Prevention states that opioids do not provide clinically meaningful pain relief and are not first line therapy for acute and chronic pain3," said Jaisim Shah, Chief Executive Officer and President of Scilex.
NURO

Hot Stocks

09:07 EDT NeuroMetrix to exhibit Quell Fibromyalgia, new clinical data - NeuroMetrix will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell in patients with fibromyalgia will be presented. Fibromyalgia is a chronic condition characterized by generalized pain, fatigue, poor sleep, memory and concentration impairments, mood disorders and other disabling symptoms. The prevalence of fibromyalgia is estimated to be 2 to 6 percent of the U.S. adult population Quell Fibromyalgia utilizes proprietary wearable neuromodulation technology and is the only FDA authorized medical device to help reduce the symptoms of fibromyalgia. Conference attendees are encouraged to visit the Company's booth #32 for a demonstration and to review prescribing details. The two scientific posters listed below will be presented live on Friday, March 24 and will be available for review throughout the conference. Wearable Lower-Extremity Transcutaneous Electrical Nerve Stimulation May Improve Self-Reported Balance Impairment in Subjects with Fibromyalgia: An Exploratory Post-Hoc Analysis Balance impairment and falls are common in individuals with fibromyalgia. Data from a recently completed double-blind, randomized, sham-controlled trial of Quell in 119 subjects with fibromyalgia was analyzed. Self-reported balance impairment was assessed on an 11-point numerical rating scale. The median balance at baseline was 5. Balance impairment decreased following 3-months of active but not sham treatment. The group difference was significant. Quell may improve self-reported balance impairment in patients with fibromyalgia. Fibromyalgia Patients with Self-Reported Weather Insensitivity Exhibit an Enhanced Treatment Response to Wearable Lower-Extremity Transcutaneous Electrical Nerve Stimulation Most individuals with fibromyalgia report that weather changes exacerbate their symptoms. However, little is known about the minority that is insensitive to the effects of weather. An analysis of real-world data from 766 individuals with fibromyalgia was conducted. Participants without weather sensitivity reported greater reductions in pain-intensity, pain-interference with sleep and pain-interference with activity compared to those with weather sensitivity. If the treatment benefits of weather insensitivity can be determined, it may be possible to optimize outcomes in the overall population of fibromyalgia patients.
CPLP

Hot Stocks

09:06 EDT Capital Product Partners announces new time charter for M/V Akadimos - Capital Product Partners announced that it has agreed a new time charter for the M/V Akadimos with a major liner company. The charter for the M/V Akadimos is expected to commence in the second quarter of 2023 in direct continuation of her present charter with a duration of approximately 24 months. The Partnership estimates that this charter may generate $34.4 million of gross revenue. As a result of the above employment update, the Partnership's charter coverage for the remainder of 2023 and 2024 has increased to 96%.
FAT

Hot Stocks

09:05 EDT Fat Brands' Pretzelmaker opens first drive-thru location in Iowa - Pretzelmaker, home of the Original Pretzel Bites, has officially rolled into its first drive-thru location in Mason City, IA with its Fresh Twist brand in partnership with franchisee, Mark Frandle. "We are thrilled to debut Pretzelmaker's first drive-thru location to date in Mason City with our franchisee, Mark Frandle, who had the vision to bring this to life in his local community," said Jenn Johnston, President of FAT Brands' Quick-Service Division. "Our Fresh Twist model was designed to cater to smaller footprints and on-the-go customers, so we see this opening as a perfect jump-start to fuel additional drive-thru growth in the years to come."
ADIL

Hot Stocks

09:04 EDT Adial Pharmaceuticals engages The Keswick Group - Adial Pharmaceuticals announced it has engaged The Keswick Group, a biotech strategic commercial and business development advisory firm, to advance the Company's partnering activities. The Keswick Group is led by Tony Goodman, a current member of Adial's board of directors. Goodman's career spans over 23 years in the pharmaceutical and biotech industries. He is the founder and Managing Director of The Keswick Group. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "Following our latest analysis of the ONWARD data... we are actively advancing discussions with a variety of potential strategic partners that could enable us to bring AD04 to large markets in the most cost-effective and timely manner. As a result, Adial's management and board of directors decided that this was the appropriate time to engage an experienced executive solely focused on identifying, evaluating and advancing our strategic options."
FTK

Hot Stocks

09:04 EDT Flotek falls over 6% in pre-market after Q4 report misses estimates
AJG

Hot Stocks

09:01 EDT Arthur J. Gallagher acquires Viking Bond Service - Arthur J. Gallagher acquired Phoenix, Arizona-based Viking Bond Service. Terms of the transaction were not disclosed. Founded in 2002, Viking Bond Service is a surety bond agency specializing in commercial, contract and fidelity bonds for clients across the U.S. Tom Buckner, Bill Belpedio and their team will operate under the direction of Kevin Garvin, head of Affinity North America for Gallagher's retail property/casualty brokerage operations.
NEOG

Hot Stocks

08:55 EDT Neogen up 2% after announcing Viroxide Super granted new label claims
SOBR

Hot Stocks

08:52 EDT Sobr Safe up 7% after announcing distribution pact with Alco Prevention Canada
MANU

Hot Stocks

08:51 EDT Manchester United expects bids of more than GBP 5B, The Times says - Manchester United expects bids for the club of more than GBP 5B, said Matt Lawton of The Times, who adds that the Qataris remain favorites, but that Jim Ratcliffe, the billionaire owner of Ineos, impressed club officials during meetings. Reference Link
EVFM

Hot Stocks

08:50 EDT Evofem implements cost reduction measures - Evofem Biosciences has implemented measures to lower its operating expenses, with the goal of reaching cash flow break even by year-end 2023. These measures include a 39% reduction of payroll expenses through a combination of salary cuts for certain employees, including a 40% reduction in CEO compensation and a 20% reduction in pay for other continuing members of the executive team vs. prior year levels; consolidation of three sales territories; elimination of eight office and management positions, including the Chief Commercial Officer role, effective March 17. The company expects this reduction in force to be substantially completed in Q1.
NEOG

Hot Stocks

08:47 EDT Neogen's Viroxide Super granted new label claims in U.S. and Canada - Neogen announced that the EPA has approved additional virucide claims to its Neogen Viroxide Super disinfectant. These label claims specify that Neogen Viroxide Super kills viruses on hard non-porous surfaces that cause Avian Influenza A, Bovine Viral Diarrhea, Porcine Respiratory and Reproductive Syndrome, and African Swine Fever. In Canada, Health Canada has also approved additional kill claims on non-porous surfaces for viruses that may cause African Swine Fever and Porcine Epidemic Diarrhea. Neogen Viroxide Super is a peroxygen-based powder disinfectant that offers broad-spectrum disinfection when used as part of a comprehensive biosecurity program.
ALT

Hot Stocks

08:46 EDT Altimmune falls 35% to $7.15 after initerim MOMENTUM Phase 2 trial data
CSIQ

Hot Stocks

08:44 EDT Canadian Solar up 9% at $39.02 in pre-market after Q4 earnings beat
BFRG

Hot Stocks

08:43 EDT Bullfrog AI now featured on Webull Corporate Communications services platform - BullFrog AI announces it is now featured on the new Webull Corporate Communication services platform. The BullFrog AI portal on the Webull platform will help provide the Company with a direct line of communication with its shareholders while providing BullFrog AI's followers with instant notifications regarding corporate content like company news, earnings reports, investor presentations, and more. "We're excited to be part of a select group of listed companies featured on Webull, a leading mobile-first brokerage platform with a unique community-driven experience," said BullFrog AI's founder and CEO, Vin Singh. "The Webull platform will enable BullFrog AI to take advantage of a convenient and efficient digital communications channel to reach the platform's more than 1.3 million active investors while also allowing us to easily share content with them in real-time."
HTCR

Hot Stocks

08:42 EDT HeartCore Enterprises partners with Works Application, AIM Consulting - HeartCore Enterprises has partnered with Works Application and AIM Consulting, to improve their respective digital auditing solutions through its DX suite of offerings. HeartCore will implement its Digital Transformation tools such as robotic process automation, process mining and task mining, into WAP's "HUE Works Suite," a series of SaaS offerings including workflow and work breakdown structure tools, and AIMC's consulting and auditing services; the integrations provide improved sets of solutions for both WAP and AIMC, allowing them to now offer their end-customers with optimized internal auditing capabilities. "HeartCore's DX offerings have augmented WAP and AIMC's value proposition to customers by increasing their capabilities," said Company CEO Sumitaka Yamamoto. "...We look forward to continually providing dynamic elements of HeartCore's comprehensive and expanding suite of services to not only meet the needs of our customers but to help enhance our partners' solutions in tandem."
SKWD

Hot Stocks

08:41 EDT Skyward Specialty Insurance enters global agricultural market - Skyward Specialty Insurance Group has entered the global agriculture market. The Company appointed James Tran as Senior Vice President, Global Agriculture, to spearhead its entry into this market. Tran most recently served as the Managing Partner at Jasperian Consulting, Inc. Global Agriculture. Skyward Specialty's global agriculture unit will initially offer secondary and reinsurance solutions for food and fiber crops, timber, livestock, bloodstock, aquaculture, and other renewable resources.
RARE

Hot Stocks

08:40 EDT Ultragenyx reports inducement grant under Nasdaq listing rule - Ultragenyx Pharmaceutical reported the grant of non-qualified stock options to purchase an aggregate of 7,130 shares of common stock of the company and 5,885 restricted stock units of the company's common stock to ten newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 16, 2023, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates. The stock options vest over four years, with 25% of the shares underlying the option vesting on the first anniversary of the grant date and the remainder vesting with respect to 1/48th of the shares underlying the options on each monthly anniversary thereafter, subject to the employee being continuously employed by the company as of such vesting dates. The stock options have a ten-year term and an exercise price of $40.22 per share, equal to the per share closing price of Ultragenyx's common stock on March 16, 2023.
CGRN

Hot Stocks

08:40 EDT Capstone gets follow-on order from Wyoming gas compression facility, no terms - Capstone Green Energy Corporation announced that Horizon Power Systems, Capstone's exclusive distributor for the Rocky Mountain States, Western Canada, Oklahoma, and Arizona, secured a follow-on order for two Capstone C1000 Signature Series microturbines. The order is scheduled to be commissioned during the third quarter of 2023. "Capstone microturbines create loyal customers, and this order is a great example. This customer has been using Capstone Green Energy microturbine technology since 2010, and continues to return for additional systems," said Darren Jamison, President and Chief Executive Officer of Capstone Green Energy. "They have implemented our low emission systems at multiple, remote, unstaffed facilities across their operations in Wyoming. Capstone microturbines continue to deliver reliable, low-emission power where the customer needs it most." The microturbine will power a remote natural gas compression facility and run on high-pressure natural gas or HPNG. The customer indicated that it selected Capstone based on its ongoing, positive experiences with Capstone products. Their current equipment has operated continuously for several years, despite being subjected to harsh conditions and extreme weather events. "The customer's current fleet of 15 microturbines have an average 99% uptime," said Sam Henry, President of Horizon Power Systems. "The company knows the reliability and low maintenance of microturbine-based energy systems. Even with the catastrophic storms that have rolled through the Basin this year, the microturbine fleet has maintained its near-perfect uptime. Capstone microturbines meet Wyoming's stringent air quality rules and make permitting very easy," added Henry.
FEAM RMO

Hot Stocks

08:39 EDT 5E Advanced Metals appoints Susan Seilheimer Brennan as CEO - 5E Advanced Materials (FEAM) appointed Susan Seilheimer Brennan as the Company's new CEO commencing April 24, 2023. Most recently, as the CEO of NYSE listed Romeo Power (RMO), she was responsible for leading an organization which developed a suite of battery technology products designed for commercial vehicles. As CEO, Ms. Brennan will lead all facets of the Company as it progresses its business strategy to become a fully integrated globally significant producer of boron, lithium and advanced materials based in the United States of America. The Company's Principal Executive Officer, Mr. Anthony Hall, will commence an immediate process, aided by Chairman, Mr. David Salisbury, to transition the CEO function to Ms. Brennan and ensure a quick and effective handover.
QLGN

Hot Stocks

08:39 EDT Qualigen Therapeutics granted patent for QN-302 by USPTO - Qualigen Therapeutics announces the United States Patent and Trademarks Office, USPTO, has granted the Company patent number 11,560,380 for QN-302, its lead oncology investigational drug candidate, a small molecule selective transcription inhibitor with strong binding affinity to G4 complexes prevalent in cancer cells being investigated for solid tumors, including pancreatic cancer. The patent protects composition of matter for QN-302 and back-up compounds, with exclusivity to the Company into 2040. Concurrently, the Company has received Notice of Intent from the European Patent Office to grant a similar patent in the E.U. "A key pillar in the development of therapeutic drugs is a company's intellectual property portfolio," commented Michael Poirier, CEO and Chairman of Qualigen. "This particular U.S. patent is of paramount importance to us, as it protects the formulation itself and is integral to our development of QN-302. Further, it strengthens our strategic position as we complete the necessary steps toward submission of an Investigational New Drug application in the coming months. We look forward to providing additional updates as they develop."
ONON

Hot Stocks

08:38 EDT On Holding up 17% in pre-market trading at $25.21 after Q4 results and guidance
GSRM BTM

Hot Stocks

08:37 EDT Bitcoin Depot enters retail partnership with GetGo Cafe + Market - Lux Vending, LLC dba Bitcoin Depot announced a partnership with GetGo Cafe + Market, a convenience store retailer with more than 270 locations throughout western Pennsylvania, Ohio, northern West Virginia, Maryland and Indiana. Bitcoin Depot plans to install its BTMs into 125 GetGo Cafe+Market stores in multiple metropolitan areas. This strengthens Bitcoin Depot's presence throughout the Midwest and Mid-Atlantic.
QNRX

Hot Stocks

08:37 EDT Quoin Pharmaceuticals doses first patient in open label Netherton trial - Quoin Pharmaceuticals announces the dosing of the first patient in its open label clinical trial in Netherton Syndrome patients. The trial is a single arm, open label study, investigating the safety and efficacy of Quoin's lead candidate, QRX003, in Netherton Syndrome patients who are currently receiving off-label systemic therapy, primarily biologic therapy, and will continue to do so throughout the duration of the study. QRX003 will be applied once daily over a twelve-week period to pre-designated areas of the patient's body. This study, which is Quoin's second study in Netherton patients, is running concurrently with the company's double blinded vehicle controlled study and is also being conducted under the company's open Investigational New Drug. Quoin anticipates reporting topline data from this open-label study in the second half of 2023. Quoin Pharmaceuticals CEO, Dr. Michael Myers, said, "We are pleased to announce the dosing of the first patient in this study. With our two clinical studies in Netherton patients actively recruiting and dosing patients, we are very encouraged by the level of interest and enthusiasm both of them are generating in the community as a whole. If approved, QRX003 has the potential to become the standard of care for Netherton patients and our goal is to make the product as widely available as possible via a combination of our own planned commercial infrastructure in the US and Europe as well as through our global distribution partnership network that now covers 60 countries."
WKHS

Hot Stocks

08:35 EDT Workhorse Group establishes Certified Dealer Program - Workhorse Group announced the launch of its new Certified Dealer Program, an initiative to develop an official network of verified dealers that have passed the protocols necessary to safely repair and maintain the electric components of the Company's vehicles. Workhorse has engaged Kingsburg Truck Center, a work truck dealer headquartered in Kingsburg, California, as its first certified electric vehicle dealer in California. Kingsburg not only sells trucks but also specializes in installing various applications for specific industry needs, making their business model uniquely suited to sell Workhorse's products. "The launch of our Certified Dealer Program is one of the vital early steps in activating our go-to-market efforts and creating a strong foundation for both our dealers and end customers," said Workhorse CEO Rick Dauch. "We are committed to providing our customers with safe, reliable vehicles and the highest standard of service, and this new program will be an integral component to building a reliable network for sales and maintenance. The partnership with Kingsburg Truck Center expands our dealer footprint westward into California, the bellwether state for the EV market. We look forward to growing our relationship with Kingsburg and other dealers domestically as we scale production and commercialize our trucks this year."
GAME

Hot Stocks

08:35 EDT Engine Gaming appoints Lawrence Rutkowski to board of directors - Engine Gaming and Media has appointed Lawrence Rutkowski to its Board of Directors effective March 16, 2023, to serve on an interim basis until the closing of the arrangement agreement between the Company and GameSquare Esports, Inc. Mr. Rutkowski previously served on Engine Gaming's Board from January 2021 to March 8, 2023.
NAOV

Hot Stocks

08:35 EDT NanoVibronix files provisional U.S. patent application for UroShield Ultra - NanoVibronix announced it has filed a new provisional patent application with the United States Patent and Trademark Office entitled "Multiple Frequency Surface Acoustic Waves for Internal Medical Device" related to its UroShield. The Patent Application covers a recently developed enhancement to the UroShield product, UroShield "Ultra", which incorporates improvements to the Company's original UroShield. The next generation UroShield Ultra includes modified housing that is designed to improve catheter coupling and incorporates multiple actuators that work in sequence to discourage bacterial docking by delivering SAWs at multiple frequencies directly to indwelling catheters. "UroShield is, to our knowledge, the only proven, effective solution for the prevention of Catheter Associated Urinary Tract Infections , the single highest source of hospital acquired infections," stated Brian Murphy, Chief Executive Officer of NanoVibronix. "This new filing expands our portfolio of intellectual property assets and reinforces our competitive position. UroShield has been proven to be instrumental in improving outcomes for hospital patients suffering from CAUTI. We are continually seeking opportunities to improve our products and by employing cutting edge technology."
LVO

Hot Stocks

08:34 EDT LiveOne provides business update on PodcastOne. balance sheet, subscribers - LiveOne announced a business update on the planned PodcastOne spin-out, balance sheet, paid subscriber growth, and share buyback. "We are excited about the planned spin-out of PodcastOne as it will be the only pure play publicly traded podcast company. We are extending the record date to April 7, 2023 as we continue to work closely with regulators and the exchange to ensure a seamless transaction. We expect the special dividend and trading of PodcastOne to begin in April," said Robert Ellin, CEO and Chairman of LiveOne. LiveOne also reported a current cash position of $10 million, which provides the company with ample resources to support its growth and investment initiatives. Since January 1, 2023, paid subscribers have increased by 136,000, a year-over-year increase of 40%, and now exceed 2 million monthly paying members. Furthermore, LiveOne expects to reach 2.75 million paying monthly subscribers by fiscal year 2024.
METX

Hot Stocks

08:33 EDT Meten Edtechx provides update on ChatGPT use in Web 3 education platform - Meten provided updates on introducing ChatGPT to its under-construction Web 3 education platform. The company will include ChatGPT and other AI technologies in its web3 education platform composed of intelligent education products by module. The features of the platform include personalized training programs adapted according to students' learning needs and levels, allowing students to interact with ChatGPT through texts, voices and videos, a real-time feedback mechanism, content sharing that allows students to obtain educational resources anytime, anywhere and an intelligent management system optimized through data analysis and algorithm optimization. Relying on ChatGPT, the company intends to launch the platform by the end of year 2023 with a focus on the English language training market, and intends to continue to include other areas of study, such as blockchain education, to the platform. In the future, the company intends to provide services to business clients in the education industry, such as schools and training institutions.
USX

Hot Stocks

08:33 EDT US Xpress Enterprises trading halted, news pending
SOBR

Hot Stocks

08:32 EDT SOBRsafe enters distrubition agreement with Alco Prevention Canada - SOBR Safe has begun its international expansion with the signing of global distributor Alco Prevention Canada. Founded in 1989, Alco is a leading provider of preventative alcohol detection solutions, selling to more than 5,000 customers across 45 countries. It has purchased SOBRcheck inventory, and has a defined plan and dedicated resources to initially launch SOBRsafe's technology in Canada, with simultaneous introduction to its broader customer base worldwide.
VCNX

Hot Stocks

08:32 EDT Vaccinex initiates Phase Ib/2 study on pepinemab - Vaccinex announced the initiation of a single-arm open label, Phase Ib/2 study to evaluate pepinemab in combination with avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma, PDAC, NCT05102721. The principal goal of this proof-of-concept study is to investigate the safety and efficacy of the combination of pepinemab and the PD-L1 immune checkpoint inhibitor, avelumab, in patients with PDAC, with particular attention to changes in the tumor microenvironment. "We are very pleased to be working with Dr. David Linehan and his team at the University of Rochester Cancer Center and Wilmot Cancer Institute to conduct this important proof-of-concept study evaluating pepinemab and avelumab in PDAC. The team received a grant from the Gateway Discovery Award to support the trial concept," said Maurice Zauderer, CEO of Vaccinex. "Metastatic pancreatic adenocarcinoma is the third leading cause of cancer-related deaths. The profoundly immunosuppressive tumor microenvironment in PDAC remains a significant barrier to effective cytotoxic and immune based therapies. Low response rates to current chemotherapy regimens are evidenced by a 5-year survival rate of only 5-10%, underscoring the significant need for new treatment options. We believe that pepinemab has demonstrated a favorable safety profile when used in combination with the immune checkpoint inhibitor avelumab, and the combination may represent a novel treatment option for patients with this devastating disease."
QNCX

Hot Stocks

08:31 EDT Echo Lake offers to acquire Quince Therapeutics for $1.60 per share in cash - In a letter to Quice Therapeutics' board, Echo Lake Capital said, "Echo Lake Capital is pleased to submit this proposal under which we would acquire all the outstanding Common Stock of Quince Therapeutics we do not own for a price of $1.60 per share in cash. Our Proposal represents a premium of 90% to the Company's closing stock price yesterday, which we believe is very compelling as it provides shareholders with a highly certain and significant return and the ability to obtain liquidity for their shares. Our Proposal is not contingent on outside financing and we believe we can complete customary diligence and negotiate definitive documentation within 30 days. As one of your largest shareholders we believe your stock is severely undervalued. The Company currently has approximately $2.55 per share of net cash and investments, no drugs being actively marketed or developed that require cash expenditures, whatever consideration the Company receives for out-licensing NOV004, the potential to receive up to $150 million in milestone payments, and $225 million of federal net operating loss carryforwards. However, Quince's stock currently trades at 84c, has an equity market cap of only $31 million and is in danger of being delisted. Unfortunately, we believe it will be extremely difficult for the Board to significantly shrink this valuation gap because Quince has an uncertain future since the company is not marketing or developing any products, is a tiny company with a limited institutional following, and has historically disappointed investors and currently lacks credibility in the investment community. We note that the Company's stock price is down 70% since its acquisition of NOV004/Novosteo in May 2022 and down 95% since its IPO in 2019. We believe our Proposal is in the best interests of all shareholders and believe it offers shareholders a significantly more attractive risk/reward scenario than the Board's current plan. Because we so strongly believe investors will favor a sale of the Company, we highly encourage you not to pursue any significant transactions while our Proposal is outstanding. Please be aware that this Proposal is an expression of interest only, and we reserve the right to withdraw or modify our Proposal in any manner. No legal obligation with respect to a transaction shall arise unless and until execution of mutually acceptable definitive documentation. Should you have any questions, please do not hesitate to contact us. We look forward to hearing from you."
ONVO

Hot Stocks

08:24 EDT Organovo announces clinical program for FXR 314 - Organovo Holdings announced a clinical program for FXR 314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials. Further, FXR314 has FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis. Organovo's FXR program announcement updates its previous guidance that it would first begin Phase 1 trials in 2025. The Company plans to give guidance on Phase 2 timelines after an internal determination of the best path forward. The Company continues to expect to file INDs starting in 2025 from fully internally developed molecules and expects to issue additional guidance on clinical plans in the coming months.
OCEA

Hot Stocks

08:22 EDT Ocean Biomedical details novel malaria therapeutics discoveries at NIH lab - Ocean Biomedical announced today that its Scientific Co-founder, Jonathan Kurtis, MD, PhD, presented details of the Company's novel malaria treatment approach to scientists at the National Institute of Health's, NIH, Laboratory of Malaria Vaccinology and Immunology in Bethesda, MD during a meeting held last month. Building on his groundbreaking discovery that the parasite protein PfGARP is potentially a highly effective vaccine target to treat malaria, Dr. Kurtis presented data demonstrating that engagement of PfGARP is critical for regulating parasite density within the human host as it triggers the malaria parasite to kill itself. Developments shared at the meeting detail how Dr. Kurtis' team used a novel approach to capitalize on PfGARPs ability to kill parasites, targeting it for potential drug development. The data generated by Dr. Kurtis' lab has demonstrated that the family of small molecule candidates in development by Dr. Kurtis' team are highly specific for PfGARP binding, are non-toxic in multiple in vitro and in vivo systems, have excellent pharmacokinetic properties, and rapidly clear parasitemia in animal models. This discovery has allowed Ocean Biomedical to begin simultaneously pursuing the development of a novel malaria vaccine, and novel malaria therapeutics.
VAXX

Hot Stocks

08:22 EDT Vaxxinity joins TransCelerate Research and Development Consortium - Vaxxinity has joined TransCelerate BioPharma as the first emerging biotechnology organization of the trailblazing consortium that is accelerating and simplifying the research and development of innovative new therapies.
HIPO

Hot Stocks

08:22 EDT Hippo director buys $3.0M in common stock - In a regulatory filing last night, Hippo disclosed that its director Noah Knauf bought 208.5K shares of common stock on March 16th in a total transaction size of $3.0M. Shares of Hippo are up 1.8% in pre-market trading.
CGTX

Hot Stocks

08:21 EDT Cognition Therapeutics to present proteomic biomarker analyses from CT1812 - Cognition Therapeutics will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of participants in the Phase 2 SHINE and Phase 1b SPARC studies with mild-to-moderate Alzheimer's disease who were treated with either CT1812 or placebo. Results of this analysis identified biomarkers of CT1812 activity that replicated across these two independent studies and patient cohorts. These findings inform our understanding of the impact of CT1812 treatment on the network of biologic pathways associated with Alzheimer's disease progression. A detailed poster presentation will be made at the upcoming AD/PD 2023: the International Conference on Alzheimer's & Parkinson's Diseases being held in Gothenburg, Sweden from March 28 to April 1, 2023. In addition, Lisa Ricciardi, CEO of Cognition Therapeutics will be participating in a panel hosted by the Alzheimer's Drug Discovery Foundation. The panel, "Emerging Solutions: Novel Approaches to Alzheimer's Disease" will take place in the Industry Symposium, "Building the Future: Novel Approaches and Innovations in Alzheimer's Research" being held on March 29, 2023 at 11:40am local time. The panelists will discuss the need for multiple novel approaches to address neurodegenerative diseases with an emphasis on the value of rigorous and biomarker-driven clinical trials to help implement this multipronged approach.
NOGN

Hot Stocks

08:21 EDT Nogin selected by HeartBrand Beef to elevate its online customer experience - Nogin announced HeartBrand Beef as its latest customer. The-largest producer of premium Akaushi beef in the United States, HeartBrand Beef will use Nogin Intelligent Commerce technology and performance marketing services to develop a world-class online customer experience and simplify operational headaches as the company continues to grow sales and scale its business. "HeartBrand Beef is committed to delivering an online customer experience to match its premium product, while also gaining insight into its marketing performance and reach," said Jon Huberman, President and CEO at Nogin. "With its decision to leverage Nogin, HeartBrand Beef has the ecommerce and marketing side of the business handled so it can now focus on building and expanding its brand."
QUBT MSFT

Hot Stocks

08:19 EDT Quantum Computing appoints LaMacchia to technical advisory board - Quantum Computing (QUBT) announced the second appointment to its Technical Advisory Board launched on February 2, 2023. Effective immediately, Dr. Brian LaMacchia, joins US intelligence community veteran and technology strategist The Honorable James Simon, Jr who heads the Board with the mission to guide and advance the strategic evolution of QCI's technology while ensuring effective commercialization of product rollouts. Brian LaMacchia recently retired from Microsoft Corporation (MSFT) where he was a Distinguished Engineer and head of the Security and Cryptography team within Microsoft Research.
SHYF PII

Hot Stocks

08:18 EDT Shyft Group announces Kermisch joined the company's board of directors - The Shyft Group (SHYF) announced that Pamela Kermisch has been appointed to the Company's Board of Directors, effective March 20, 2023. Since January 2018, Kermisch has served as the Chief Customer Growth Officer at Polaris (PII).
LIFE

Hot Stocks

08:18 EDT aTyr Pharma to present data from tRNA synthetase candidate ATYR0101 - aTyr Pharma announced that Leslie A. Nangle, Ph.D., Vice President, Research, will present findings from its platform in an oral presentation and poster at the Keystone Symposia on Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies, which is scheduled to take place March 19 - 23 in Banff, Alberta, Canada. aTyr will present findings from its innovative tRNA synthetase platform that highlight ATYR0101, a potential therapeutic biologic based on a domain appended to Aspartyl-tRNA Synthetase that is naturally occurring and selected through evolutionary intelligence to be released from cells to modulate extracellular signaling. ATYR0101 was found to bind to human fibroblasts and extracellular matrix deposited by fibroblasts via novel binding of latent transforming growth factor beta binding protein 1. LTBP1 is an extracellular matrix protein and key regulator of transforming growth factor beta, a central player in the pathogenesis of fibrotic diseases. These findings indicate that ATYR0101 may have therapeutic potential in fibrotic pathologies.
NUWE

Hot Stocks

08:16 EDT Nuwellis announces peer-reviewed publication on trials using ultrafiltration - Nuwellis announced the peer-reviewed publication of an analysis of available ultrafiltration clinical trials with findings that support ultrafiltration as a safe and effective therapeutic option for acute decompensated heart failure, ADHF, patients who are resistant to diuretics or who have a history of multiple hospitalizations for fluid overload. The publication highlights the scale of clinical burden: "ADHF has the highest rate of hospital readmissions among all medical conditions and portends a significant financial burden on healthcare systems worldwide." The publication, "Extracorporeal Ultrafiltration for Acute Heart Failure," featured in Cardiorenal Medicine Journal, includes the review of pooled data from seven randomized controlled trials of ultrafiltration with a total of 771 patient participants. A. Kazory, et al, highlight the clinical application and value of ultrafiltration, including: Predictable, adjustable, and more efficient fluid removal with ultrafiltration compared to diuretics, without clinically adverse impact on renal function, leads to a reduction in hospital readmissions and financial burden; Applicability of ultrafiltration therapy in other clinical settings, such as cardiac surgery, burn and other specialty units, where active and prompt volume management is of utmost importance; and Expansion of use of ultrafiltration into outpatient centers and other ambulatory settings.
TMC

Hot Stocks

08:16 EDT Metals Company says Benchmark completes lifecycle assessment of NORI-D - TMC the metals company announced that lithium-ion battery supply chain research firm, Benchmark Mineral Intelligence, has completed an independent third-party lifecycle assessment of the environmental impacts of the Company's planned NORI-D Polymetallic Nodule Project as it looks to bring online the planet's largest undeveloped deposit of critical battery metals. The full LCA report can be downloaded here and a summary document here. Benchmark's team of LCA practitioners set out to assess the potential impacts of mining, transport, processing and refining ('cradle-to-gate') of important battery materials including an intermediate NiCuCo matte product and final end-products nickel sulfate, cobalt sulfate and copper cathode from seafloor polymetallic nodules collected from the NORI-D area. They then compared these impacts to producing the same metals via key land-based routes, including from Indonesian nickel laterites and mixed sulfides and oxides mined in the DRC. These raw material inputs are widely used in active cathode materials for nickel-rich cathode chemistries for lithium-ion batteries and electrical wiring, enabling the rapid growth of electrified transport and energy storage. Seven environmental impact categories critical for the metal industry were analyzed-global warming potential, stratospheric ozone depletion, terrestrial acidification, freshwater and marine eutrophication, particulate matter formation, water consumption-and supplementary research into waste generation was also conducted. Nickel, cobalt and copper products derived from the NORI-D Nodule Project performed better in almost every impact category, except for global warming potential and water consumption of producing cobalt sulfate, where one land-based route performed better. With over half of nickel now being sourced from beneath biodiverse rainforests and carbon sinks in Indonesia, the study found that TMC's nickel sulfate product would outperform not just Indonesian nickel but all other key land-based production routes, lowering emissions by between 70-80% on average, including with 70% lower GWP.
OLK

Hot Stocks

08:15 EDT Olink announces Bruno Rossi joins the company as Chief Commercial Officer - Olink Holding announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer, CCO, effective immediately. Rossi will lead the Company's global commercial organization including Sales, Marketing and Sales Operations. He will report to Carl Raimond, President of Olink. Bruno Rossi brings more than 25 years of global experience in the life sciences industry. Before joining Olink, Bruno held multiple leadership positions at Leica Microsystems most recently serving as Vice President Global Business Transformation.
OUST

Hot Stocks

08:14 EDT Ouster and LASE GmbH in multi-year deal to automate port operation - Ouster and LASE GmbH, a worldwide company in laser-based sensor applications for industrial equipment, announced the signing of their multi-year supply agreement to help further automate and retrofit container terminals and crane systems at ports with 3D digital lidar sensors. This agreement includes a binding commitment for several hundred Ouster OS sensors through 2025. LASE has thousands of existing installations using static and swiveling 2D laser scanners. LASE plans to offer new solutions utilizing Ouster's 3D digital lidar sensors to increase and enhance the capabilities of its existing and new installations. Ouster sensors are already being deployed by LASE at ports around the world, including in Poland, Chile, and the United Kingdom. The LASE system helps ensure safe container handling in and around ports, during both loading and unloading of the container ships as well as in the landside handling areas. LASE typically equips gantry cranes and other port equipment with two or four Ouster OS1 sensors for precise position measurement and object detection to enable safer autonomous or semi-automated handling of containers. This digital lidar-based solution supports collision avoidance between handling machines, people, other port equipment, as well as optimal positioning and safe lifting of cargo on trucks. Additionally, LASE uses Ouster's sensor for zone monitoring to help safeguard operations in and around the equipment in ports.
GANX

Hot Stocks

08:14 EDT Gain Therapeutics announces grant award by Eurostars with Innosuisse - Gain Therapeutics announced that Eurostars and Innosuisse have awarded a grant in the aggregate amount of EUR 1.2M to a consortium led by Gain Therapeutics which includes the Institute for Research in Biomedicine, Newcells Biotech and the University of Helsinki. This grant supports a research project to develop novel small molecule allosteric regulators against Alpha-1 Antitrypsin, AAT, Deficiency, a rare genetic condition that can result in serious lung and liver diseases. "We are pleased that Eurostars and Innosuisse recognize that Gain Therapeutics' allosteric small molecule regulators provide a new approach to address AAT deficiency-related metabolic diseases. We look forward to advancing our AAT program with this consortium, which combines our unique targeting approach with novel in vitro and in vivo models. This grant validates the capability of our computational discovery platform SEE-Tx to identify previously unknown allosteric binding sites on protein targets in CNS, oncology and now metabolic disease," said Dr. Manolo Bellotto, Chief Strategic Officer and General Manager at Gain Therapeutics.
OSA

Hot Stocks

08:14 EDT ProSomnus receives patent allowance covering automated manufacturing process - ProSomnus announced that the U.S. Patent and Trademark Office has allowed a patent application covering the Company's proprietary automated manufacturing process for the Company's precision medical devices; this is the third patent to issue in this family, including already-issued USPN 10,213,280 and USPN 9,808,327. ProSomnus's intellectual property portfolio now includes 16 issued patents in the United States and other countries, encompassing more than 100 claims, in addition to trademarks, trade secrets and other patent applications in process.
VEDU

Hot Stocks

08:12 EDT Visionary Education Technology inheriting the Spirit of Olympics - Visionary Education Technology announced that on March 16, Xia Sijun, the partner of the Company's Olympic education project, went to Athens to discuss the global cooperation plan for the "Olympic International High School" with the President, Honorary President, General Counsel, and legal staff of the IOA. The meeting was very successful, and the IOA Chairman expressed his support. The Company will prepare comprehensive and detailed documents to be submitted to the IOA, and plans to obtain the IOA's approval between April and May. One of the cores of the Olympics is education, and influencing people's behavior through the example of champions is a true reflection of the Olympic educational dream. The value of Olympic education is to enable students to participate in sports, reap the improvement of sports skills, broaden their horizons, experience the charm of Olympic culture, experience the spirit of strength, tenacity, struggle, respect, cooperation, responsibility, and never give up, and gain all-round training and growth through the accumulated training process. The Company plans to rename one of its OSSD certified high schools to Canadian Olympic International High School, creating Canada's first Olympic International High School. With global enrollment, the school will mainly recruit students who love and excel in sports, and cultivate future champions and popularize sports.
ALHC

Hot Stocks

08:12 EDT Alignment Health appoints new SVPs for core markets - Alignment Health announced the appointment of Tim Moorhead as senior vice president and regional president of North Carolina, Arizona and Texas, and Lisa Ferrari as senior vice president and regional president of Nevada and Northern California. Reporting to Dawn Maroney, president of markets for Alignment Health, both executives will create customer value while ensuring strategic operating plans are being met in their respective markets. They also will collaborate and manage relationships with area health care professionals, health systems, medical groups, independent physician associations, local legislators and other key stakeholders to deliver state-of-the-art health plan performance and support Alignment's overall growth. Before Alignment, Moorhead served as SVP and president for Ascension Insurance. Ferrari most recently served as the vice president of managed care for Rady Children's Health.
GH

Hot Stocks

08:10 EDT Guardant Health teams with Ohio State to study CRC screening adherence - Guardant Health has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute to evaluate patient compliance with a blood-based test for colorectal cancer, CRC, screening. In this study, The Ohio State University Guardant Shield Colorectal Cancer Screening Project, individuals from minority and underserved populations aged 45 and older who are in need of CRC screening will have the option to receive the Shield blood test, administered by a mobile phlebotomist, as part of their engagement with a community health van. Integrating Shield into mobile health services will allow health care providers to bring blood-based screening directly to communities making it accessible for eligible individuals who are not compliant with CRC screening. "We learned early on in the COVID-19 pandemic that we need to be innovative in how we deliver care to our communities. By deploying a mobile phlebotomist as part of a mobile health clinic, we are further able to understand the potential and ease of a blood test to reach rural and underserved communities," said AmirAli Talasaz, Guardant Health co-CEO. "The Ohio State University Comprehensive Cancer Center research team has a long legacy of community leadership in Ohio and Appalachia, so we know we are meeting patients where they are, helping to further reduce barriers to access, and improve CRC screening rates to pre-pandemic levels."
OTCM

Hot Stocks

08:10 EDT OTC Markets celebrates passing of ESOP Fairness Act Legislation - OTC Markets Group celebrates the ESOP Fairness Act, which was included in the SECURE Act 2.0 retirement package that was signed into law on December 29, 2022. We thank the lead sponsors Representative Brian Higgins and Senator Gary Peters who advocated for the inclusion of this important provision, along with Senators Thom Tillis and Kyrsten Sinema, and Representatives Mike Kelly, Vern Buchanan, Linda Sanchez, Jackie Walorski, Darin LaHood and Bill Pascrell. Employee Stock Ownership Plans are benefit plans recognized under IRS regulations that allow companies to offer stock ownership to their employees in a tax-efficient manner. Section 123 of the SECURE Act 2.0 will allow qualifying companies trading on the OTCQX Best Market and OTCQB Venture Market to offer ESOPs to their employees under the same rules as exchange-traded companies. With approximately 800 OTCQX and OTCQB companies meeting the criteria under the ESOP Fairness Act, the OTC Markets Group team played an active role in advocating for this legislation on behalf of these companies and their many employees.
INSP

Hot Stocks

08:09 EDT Inspire Medical announces FDA approval for pediatric patients with Down Syndrome - Inspire Medical Systems announced that it has received approval from the Food and Drug Administration, FDA, to offer Inspire therapy to pediatric patients with Down syndrome. "Since our first FDA approval in 2014, the research team at Mass Eye and Ear, led by Dr. Christopher Hartnick, have pioneered the use of Inspire in this important group of people and we are thrilled to announce this most impactful approval on World Down Syndrome Day," said Tim Herbert, President and Chief Executive Officer of Inspire. "We acknowledge and appreciate the persistence of Dr. Hartnick's team, as well as the teams at the many participating institutions, to collect the necessary clinical evidence to support the FDA approval. We would also like to thank the LuMind IDSC Down Syndrome Foundation for their support of our FDA application. Inspire intends to immediately begin educating healthcare providers across the U.S. about the benefits of Inspire therapy for children with Down syndrome." Inspire has been prescribed to adults with Down syndrome for several years, but previously only to patients who were at least 18 years of age. Approval of the pediatric population with Down syndrome will include OSA patients who are at least 13 years old, with an apnea hypopnea index between 10 and 50, and do not have the ability to benefit from CPAP.
CELL

Hot Stocks

08:09 EDT PhenomeX appoints Yan Zhang as Chief Commercial Officer - PhenomeX has named Yan Zhang Chief Commercial Officer effective immediately. PhenomeX has also named Tomoya Aoyama Regional Leader, overseeing the company's commercial operations in APAC. Zhang joins PhenomeX with nearly 25 years of executive management and operating experience in the life science tools industry. Over the last two years, she has served as CEO and a member of the board at Mission Bio, a life sciences company focused on high-throughput single-cell DNA and multi-omics analysis. Before Mission Bio, Zhang served in executive roles at Thermo Fisher Scientific. She also led product management and commercialization efforts for genetic analysis solutions at Affymetrix, NuGEN Technologies, and Molecular Devices. Aoyama has more than 25 years of experience in Asia in management roles at multinational, public life sciences companies.
ECOR

Hot Stocks

08:08 EDT electroCore's Truvaga users reported improved wellness in recent focus group - electroCore announced the results of a Truvaga focus group study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, the Truvaga product helped its users improve stress, anxiety, sleep, energy, and mood. In the in-home focus group study, 34 participants were instructed to use the Truvaga product twice a day for 30 days to assess the product's benefits and overall user experience. Self-assessment evaluations were reported after 7 and 30 days. After 30 days, users reported the following: 94% felt calmer; 91% felt their mood improved; 88% felt less anxious; 85% felt an improvement in stress; 82% felt more alert; 77% had more energy; and 74% felt they sleep better. After the study was completed, 86% of users said they will continue to use the product for ongoing overall wellness benefits. "I am thrilled about the initial launch of our wellness product, Truvaga," stated Michael Mansfield, VP, Marketing at electroCore. "The initial response and testimonials we received are a reminder of the benefits that can be realized by using vagus nerve stimulation and I look forward to building the Truvaga brand during 2023 through ecommerce and affiliate channels."
FMBH BHWB

Hot Stocks

08:07 EDT First Mid Bancshares to acquire Blackhawk Bancorp for $90.3M - First Mid Bancshares (FMBH) and Blackhawk Bancorp (BHWB) announced the execution of a definitive agreement under which Blackhawk will merge with First Mid in a 100% stock transaction.Blackhawk is the parent company of Blackhawk Bank and is headquartered in Beloit, Wisconsin, operating 10 branches in Wisconsin and Illinois. As of December 31, 2022, Blackhawk had approximately $1.32 billion in total assets, $782 million in loans and $1.19 billion in deposits. Blackhawk has been a pillar of the Beloit community since 1881 and expanded into northern Illinois in 1996. Under the terms of the agreement, First Mid will acquire 100% of the outstanding shares of Blackhawk and Blackhawk shareholders will receive 1.15 shares of FMBH common stock for each share of BHWB common stock. Based on First Mid's price per share at closing on March 20, 2023 of $27.13, the aggregate consideration to be paid by First Mid is approximately $90.3 million, subject to certain conditions and adjustments. The transaction is estimated to be approximately 22% accretive to earnings per share in 2024. Estimated tangible book value per share dilution to First Mid is expected to be earned back in 1.9 years under the crossover method. First Mid expects to achieve cost savings of approximately 31% of Blackhawk's noninterest expense. While revenue synergies are anticipated, they have not been included in the estimates. As of December 31, 2022, Blackhawk had a loan-to-deposit ratio of approximately 65% and a fourth quarter cost of deposits of 0.51%. In addition, Blackhawk had only 8.5% of its balances as uninsured deposits. All of these ratios strengthen the funding sources for First Mid. Based on the December 31, 2022 ratios, the pro forma company will have a loan to deposit ratio of approximately 85%, a pro forma cost of deposits of 0.67%, and pro forma uninsured deposits of only 21%. In addition to these benefits, Blackhawk's available for sale securities portfolio of approximately $444 million at December 31, 2022 will be marked to fair value through purchase accounting at the close of the transaction. This will provide significant flexibility and an additional liquidity source for the combined company. The transaction has been unanimously approved by each company's board of directors and is expected to close in the second half of 2023, subject to regulatory approvals, the approval of Blackhawk's stockholders and the satisfaction of customary closing conditions.
BIVI

Hot Stocks

08:07 EDT BioVie announces data from Phase 2 PD trial - BioVie announced data from its Phase 2 Parkinson's Disease, PD, trial will be presented at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, AD/PD 2023, to be held March 28 - April 1, 2023 in Gothenburg, Sweden. Data from the Company's Phase 2 Trial evaluating NE3107 in Parkinson's Disease will be presented orally during the symposium Advances in PD and LDB Diagnosis and Drug Development. A poster presentation on the pharmacokinetic profile of NE3107 will also be given. Both the oral presentation and poster will be available virtually throughout the event.
F

Hot Stocks

08:06 EDT Ford selects John Dion to be chief transformation officer - Ford has chosen a new senior leader to drive its rigorous and relentless pursuit of high quality, simplicity and low costs on behalf of customers and other stakeholders, the company announced. John Dion will join the company as chief transformation officer on April 3, reporting to Ford CEO Jim Farley. Dion will oversee global deployment of methodologies and tools based on Lean manufacturing and related concepts, capabilities that are central to realizing the value-creation and growth potential of the company's Ford+ plan.
ACDC

Hot Stocks

08:04 EDT ProFrac Holding provides outlook for 2023 - ProFrac Holding provided an outlook for its 2023 operations. Lower commodity prices have impacted customers' business over the last several months. Pricing levels have remained steady through February, but the company will continue to assess the market dynamics. In response to the sharp reduction in gas prices, the company has seen a less efficient calendar develop over the course of Q1. The less efficient calendar combined with the seasonal winter weather impacts is expected to slightly reduce the company's efficiencies in Q1 vs. 4Q22. The startup of operations at the Lamesa mine along with the acquisition of Monarch Silica, both in December, should allow the company to operate approximately five mines during Q1. This should serve to increase the number of fully integrated fleets and materials sales. The acquisition of Performance Proppants in late February will result in the Company exiting the quarter with a total of eight operating mines. The company expects to enhance profit per fleet as it further integrates materials into its operating fleets, however Adjusted EBITDA per fleet will also be impacted by inefficiencies and fleet pricing trends in the market.
JRSH

Hot Stocks

07:46 EDT Jerash Holdings, Busana enter agreement to form JV for sportswear, outerwear - Jerash Holding and Busana Apparel Group signed an agreement to form a joint venture company for producing custom, ready-made, sportswear and outerwear in Jordan for Busana's global branded customers. The new company will operate under the name, J&B International Limited, and will bring together two of the industry's leading apparel manufacturers, serving many iconic, high-profile global brands. Busana is supported by more than 28,000 employees worldwide and has 30 manufacturing facilities in Indonesia and Ethiopia. Jerash has long-established manufacturing operations in Jordan, with plans in place for further capacity expansion. As part of the agreement, Jerash will own a 51 percent equity stake in the joint venture, and Busana will own 49 percent. The companies will contribute a proportionate amount of $1.5 million as working capital to launch the new entity.
JPM

Hot Stocks

07:45 EDT Campbell Lutyens and J.P. Morgan announce collaboration in 2NDRY advisory market - Campbell Lutyens and J.P. Morgan are pleased to announce the establishment of a strategic collaboration to jointly offer their advisory services on single-asset and concentrated multi-asset continuation fund secondary transactions. The offering will enable clients to benefit from Campbell Lutyens' and J.P. Morgan's global, market leading secondary and Investment banking advisory practices, respectively. The proposition combines J.P. Morgan's global top-tier investment banking services with Campbell Lutyens' leading global placement and secondary advisory platform, creating a best-in-class global offering for single-asset and concentrated multi-asset continuation funds. It will be available for clients across all regions and sectors in which Campbell Lutyens and J.P. Morgan both operate. The offering provides access to Campbell Lutyens' secondaries expertise focused on fund structuring and capital raising from secondaries and institutional investors along with J.P. Morgan's M&A services, industry expertise and capital raising capabilities. "We are delighted to be working with J.P. Morgan and believe that our combined capabilities and experience offer a compelling proposition in the secondary advisor market," said Immanuel Rubin, head of European and Asia Pacific secondary advisory and Gerald Cooper, head of North American secondary advisory at Campbell Lutyens. "Our clients will now have the option to benefit from the resources and expertise of both of our franchises when seeking to complete these types of complex secondary transactions."
NEXCF

Hot Stocks

07:44 EDT Nextech3D.ai files second generative AI patent for 3D model creation - Nextech3D.AI announced the Company has filed a second in a series of patents for converting 2D photos to 3D models. Patent filing title: "Fixed-point diffusion for robust 2D to 3D conversion and other applications." A major contributor to Nextech3D.ai's 3D modeling success and ability to meet market demand is its Generative Artificial Intelligence. This patent builds on the Company's previous patents filed. Earlier this month, a patent was filed titled "Generative AI for 3D Model Creation from 2D Photos using Stable Diffusion with Deformable Template Conditioning", and late last year the Company filed a patent for creating complex 3D models by parts. The game-changing AI technology underpinning these patents places the Company in a leadership position in the 3D modeling for ecommerce space and positions the Company to generate significant revenue acceleration and cash flow in 2023 and beyond. Building on the Company's previous patents, Nextech3D.ai will be using fixed-point diffusion for learning to construct 3D models from 2D reference photos, starting with simpler objects, and individual parts, before expanding to more complex, multi-part objects.
CNNEF

Hot Stocks

07:42 EDT Canacol Energy reports conventional natural gas, crude oil reserves - Canacol Energy is pleased to report its conventional natural gas and light/medium crude oil reserves for the fiscal year end December 31, 2022. The Corporation's conventional natural gas reserves are located in the Lower Magdalena Valley basin, Colombia. Newly discovered light/medium crude oil reserves are located in the Middle Magdalena Valley basin, Colombia. Highlights: Conventional Natural Gas and Light/Medium Crude Oil Proved + Probable Reserves: Increased by 7.5% since December 31, 2021, totaling 652 billion standard cubic feet equivalent at December 31, 2022, with a before tax value discounted at 10% of $1.9B, representing both C$76.67 per share of reserve value, and C$53.79 per share of 2P net asset value; Reserve replacement of 169% based on calendar 2022 conventional natural gas and light/medium crude oil reserve additions of 79.5 Bcf and 5.7 MMBbls, respectively, totaling 112 Bcfe; 2P Finding and Development Cost of $1.87 / Mcfe for the three-year period ending December 31, 2022; Recycle ratio of 1.7x for the year ended December 31, 2022; Recycle ratio of 1.9x for the three-year period ending December 31, 2022; Reserves life index of 10.0 years based on annualized fourth quarter 2022 conventional natural gas production of 177,985 thousand standard cubic feet per day or 31,225 barrels of oil equivalent per day; RLI of 8.7 years based on conventional natural gas production guidance of 206,000 Mcfpd for calendar 2023. Conventional Natural Gas and Light/Medium Crude Oil Total Proved Reserves: Decreased by 7.9% since December 31, 2021, totaling 339 Bcfe at December 31, 2022, with a before tax value discounted at 10% of $1B, representing both C$39.32 per share of reserve value, and C$16.43 per share of 1P net asset value; Reserve replacement of 56% based on calendar 2022 conventional natural gas and light/medium crude oil reserve additions of 31.5 Bcf and 1.0 MMBbls, respectively, totaling 37 Bcfe; Concurrent drilling operations through to year end resulted in discoveries at Chimela on the VMM45 block, Saxofon on the VIM5 block, and Dividivi on the VIM33 block. However, by the December 31, 2022 effective date of the report, limited production testing could occur impacting 1P reserve bookings. 1P F&D of $2.60 / Mcfe for the three-year period ending December 31, 2022; RLI of 5.2 years based on annualized fourth quarter 2022 conventional natural gas production of 177,985 Mcfpd or 31,225 BOEPD; RLI of 4.5 years based on conventional natural gas production guidance of 206,000 Mcfpd for calendar 2023. Conventional Natural Gas and Light/Medium Crude Oil Total Proved + Probable + Possible Reserves: Increased by 14.3% since December 31, 2021, totaling 1,088 Bcfe at December 31, 2022, with a before tax value discounted at 10% of $3.1B, representing both C$124.36 per share of reserve value, and C$101.48 per share of 3P net asset value;Reserve replacement of 304% based on calendar 2022 conventional natural gas and light/medium crude oil reserve additions of 124.8 Bcf and 13.6 MMBbls, respectively, totaling 202 Bcfe. 3P F&D of US$1.05 / Mcf for the three-year period ending December 31, 2022; RLI of 16.8 years based on annualized fourth quarter 2022 conventional natural gas production of 177,985 Mcfpd or 31,225 BOEPD; RLI of 14.5 years based on conventional natural gas production guidance of 206,000 Mcfpd for calendar 2023.
ENVB

Hot Stocks

07:40 EDT Enveric establishes Australia-based unit to advance EVM201 Series for anxiety - Enveric Biosciences announced that it has established Enveric Therapeutics, an Australia-based subsidiary, to support the Company's plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic. Enveric Therapeutics will oversee the Company's preclinical, clinical, and regulatory activities in Australia, including ongoing interactions with the local Human Research Ethics Committees, HREC, and the Therapeutic Goods Administration, TGA, Australia's regulatory authority. Enveric's lead drug candidate, EB-373, is a next-generation synthetic New Chemical Entity , NCE, designed as a psilocin prodrug and developed leveraging its Psybrary drug discovery platform. Enveric expects to initiate a Phase 1 first-in-human clinical trial investigating EB-373 targeting anxiety disorders in the fourth quarter of 2023. "Australia is an ideal location to advance the development of EB-373, as well as additional future therapies generated from our EVM201 and EVM301 Series, given the favorable clinical, regulatory and cost-saving opportunities available to biotechnology companies, particularly those advancing psychedelic-derived compounds for CNS conditions," said Joseph Tucker, Ph.D., Director and CEO of Enveric Biosciences. "With the establishment of Enveric Therapeutics Pty. Ltd., we now have a foothold in Australia that we expect will enable us to efficiently and expeditiously advance our lead program towards generating human data by early 2024."
FCN

Hot Stocks

07:40 EDT FTI Consulting announces partnership with NetDocuments - FTI Consulting announced that the firm's Technology segment has entered into a partnership with NetDocuments, a trusted cloud content platform for legal professionals. This partnership will allow FTI Technology's Corporate Legal Operations practice to provide clients with more flexible and integrated native cloud-based solutions for core legal department functions, such as document and content management. Wafik Guirgis, a Senior Managing Director and global Co-Leader of FTI Technology's Corporate Legal Operations practice, said, "To better serve the needs of our clients in each of these areas, and as an extension of our ongoing strategic expansion of our corporate legal operations offerings, we're developing partnerships with leading solutions providers like NetDocuments. Working across the legal technology ecosystem, FTI Technology supports clients in improving their return on technology investments and accelerating adoption of tools that improve overall efficiency and empower collaboration and knowledge sharing."
AEHR

Hot Stocks

07:38 EDT Aehr Test receives order from major silicon carbide semiconductor customer - Aehr Test Systems announced it has received an order from its second major silicon carbide semiconductor customer for production quantities of WaferPak full wafer Contactors to be used with previously ordered FOX-XP(TM) systems for test and burn-in of silicon carbide semiconductor wafers in their production facility. Shipments of these WaferPaks will begin in Aehr's current fiscal fourth quarter that began March 1, 2023. Gayn Erickson, President and CEO of Aehr Test Systems, commented, "We are excited to receive this order reflecting initial WaferPak purchases from this customer for use in volume production of devices to meet the incredible demand for silicon carbide power semiconductors used in power conversion applications for electric vehicles. We believe that this customer will purchase a large number of our FOX-XP systems to meet their publicly announced significant increase in planned capacity and revenue growth over the next several years and through the end of the decade."
CNET

Hot Stocks

07:37 EDT ZW Data Action Technologies announces cooperation with Haishuyun - ZW Data Action Technologies announced that it entered into a partnership with Guangzhou Haishuyun Technology. The two parties will explore cooperative solutions for the development of chain brands, while supporting traditional industries and brands, assisting customers in achieving digital transformation in taxation, aggregated payments, and providing clients with diversified value-added services. In this collaboration, Haishuyun and ZW Data will leverage their respective strengths and advantages in blockchain technology, financial and tax consulting, aggregated payment technology, and franchise expertise to integrate resources and channels. While providing franchise services, ZW Data, together with Haishuyun, will offer convenient, efficient, and compliant "payment + split account + tax planning" SaaS tools and other value-added services to thousands of franchise brands and franchisees, providing clients with the optimal financial and tax compliance paths. "The seamless integration of resources between ZW Data and Haishuyun aligns with the financial, tax, and payment digitization requirements of traditional industry enterprises and brands. Our professional and practical financial, tax, and payment value-added services are set to become a 'stable accelerator' for high-quality brands, bolstering ZW Data's expansion support for clients," commented Handong Cheng, Chairman and Chief Executive Officer of ZW Data.
IMTX

Hot Stocks

07:36 EDT Immatics sees cash runway into 2025 - Cash and cash equivalents as well as other financial assets total EUR 362.2 million as of December 31, 2022 compared to EUR 145.1 million as of December 31, 2021. The increase is mainly due to our public offering and upfront payments for collaborations, partly offset by our ongoing research and development activities. The Company projects a cash runway into 2025.
BBIO

Hot Stocks

07:35 EDT BridgeBio shares preliminary findings on glycosylated alpha-dystroglycan - BridgeBio Pharma announced the Company's novel validated muscle tissue-based bioassay, which measures the amount of glycosylated alpha-dystroglycan, alphaDG, in patients with LGMD2I, at the MDA 2023 Annual Meeting. Additionally, BridgeBio shared updated results at Month 15 for its Phase 2 clinical trial and the design for its pivotal Phase 3 study for patients with LGMD2I. The novel bioassay was developed by BridgeBio to measure the amount of glycosylated alphaDG, and to evaluate the impact of BBP-418 treatment. When deficient, glycosylated alphaDG is the direct cause of muscle breakdown in LGMD2I. The bioassay allowed the Company to evaluate natural history and Phase 2 data to inform the Phase 3 study design. Highlights of the results include: Development of a novel, validated, quantitative method to measure glycosylated alphaDG in muscle; Observation of ~90% reduction in glycosylated DG in muscle biopsies from patients with LGMD2I compared to healthy individuals; Higher glycosylated DG in L276I/L276I homozygous patients who are characterized by a milder clinical phenotype than other fukutin-related protein genotypes; Stable glycosylated DG levels in untreated patients with LGMD2I over ~6-12 months. Additionally, BridgeBio presented 15-month results from its ongoing Phase 2 trial and the design of its registration-enabling Phase 3 study. Phase 2 study results showed: Increased glycosylation of alphaDG was observed following treatment initiation with BBP-418, with an approximate doubling of glycosylated alphaDG at 3 months which was sustained over 15 months; Greater than 70% reduction in CK sustained at 15 months; Improvements from baseline in NSAD test scores and ambulatory measures at 15 months; No treatment-related serious adverse events or dose limiting toxicities were observed with BBP-418.
SNSE

Hot Stocks

07:32 EDT Sensei Biotherapeutics submits IND application for SNS-101 - Sensei Biotherapeutics announced the submission of an Investigational New Drug, IND, application to the U.S. Food and Drug Administration, FDA, for a Phase 1/2 clinical trial of SNS-101, a conditionally active VISTA-blocking antibody, in patients with solid tumors. SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to selectively block the VISTA checkpoint in the tumor microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1. Sensei plans to evaluate SNS-101 as a novel treatment for patients with solid cancers, as both a monotherapy and in combination with other therapies.
NVTA

Hot Stocks

07:32 EDT Invitae partners with Epic to streamline genetic testing - Invitae announced a partnership with Epic, a healthcare software company. Invitae's mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Through Aura, Epic's specialty diagnostics suite, Invitae will streamline interactions with provider organizations in the Epic community, making test result information available in providers' usual workflows so that it's easier to use genetic insights to inform treatment decisions.
NTLA

Hot Stocks

07:31 EDT Intellia Therapeutics announces FDA granted RMAT to NTLA-2002 - Intellia Therapeutics announced that the U.S. Food and Drug Administration, FDA, granted Regenerative Medicine Advanced Therapy, RMAT, designation to NTLA-2002 for the treatment of hereditary angioedema, HAE. NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to inactivate the target gene, kallikrein B1, to potentially prevent life-threatening swelling attacks in people with HAE. "The RMAT designation is important recognition for our early clinical data. It indicates that a single dose of NTLA-2002 has the potential to address serious unmet medical need for people living with hereditary angioedema," said Intellia President and Chief Executive Officer John Leonard, M.D. "We look forward to continuing our productive dialogue with the FDA to accelerate the development of NTLA-2002, an investigational in vivo CRISPR-based therapy, with the goal of bringing forth a potentially transformative treatment to patients more quickly."
NNDM

Hot Stocks

07:25 EDT Nano Dimension releases video on deep learning for industrial applications - Nano Dimension released a video in which Dr. Eli David analyzes and describes the route from archaic Artificial Intelligence to NANO's Deep Learning for Industrial Applications and Additive Manufacturing.
AIMD

Hot Stocks

07:24 EDT Ainos enters distribution agreement with Topmed for VELDONA in Taiwan - Ainos has signed a distribution agreement with Topmed International Biotech. Under the Agreement, Topmed will be the exclusive distributor of pet supplements for cats and dogs based on Ainos' low-dose oral interferon-alpha formulation, VELDONA, in Taiwan. The supplement for cats aims to improve immunity and dental health, and the supplement for dogs aims to improve immunity and skin health.
VOXR...

Hot Stocks

07:22 EDT Vox Royalty provides project updates across gold royalty portfolio assets - Vox Royalty (VOXR) provides recent North American development and exploration updates from royalty operating partners Treasury Metals, Alamos Gold (AGI), and Orla Mining (ORLA). Spencer Cole, Chief Investment Officer stated: "We are excited to report promising development progress across key Canadian and US development gold royalties, including the release of the Goldlund-Goliath pre-feasibility study, major permitting milestones at Lynn Lake, and exploration success at South Railroad. Vox's ~80% weighting to Canada, USA and Australia is further unpinned by the advancement of these North American development projects. In an ever-changing global geopolitical landscape, Vox's growth pipeline in these three Tier 1 mining jurisdictions continues to support management confidence around Vox's long-term value creation for our shareholders." Key Updates: Treasury announced positive results for its pre-feasibility study over the Goldlund gold project, which is part of the Goliath Gold Complex in Ontario; Major permitting milestones were achieved by Alamos at the Lynn Lake gold project, with the completion of an Environmental Impact Assessment and a positive Decision Statement issued by the Minister of Environment and Climate Change Canada; and Significant South Railroad gold drilling results were announced by Orla, with continued resource expansion exploration drilling scheduled for 2023 in Nevada.
DECPF

Hot Stocks

07:19 EDT Diversified Energy reports 2022 average daily production 135 MBoepd - Reports 2022 net loss $620M, revenue $1.9B. Commenting on the results, CEO Rusty Hutson, Jr. said: "2022 was another productive year for Diversified, growing our high-quality asset base, optimizing our production, continuing our vertical integration, generating significant Free Cash Flow, and returning meaningful capital to shareholders through dividends and share repurchases. We delivered a 49% increase in total hedged revenue resulting in approximately 50% margins for the fifth consecutive year, driven by our disciplined hedging strategy. This translated into Diversified ranking in the top 20 of total shareholder returns in the FTSE 250 for the year. As the Company enters 2023, the progress we made during the past year, both financially and operationally, puts Diversified in a strong position for the expanding opportunity set that lies ahead. Our prudent hedge position of approximately 85% of the year's current production with a floor of approximately $3.83 per Mcf, well above forecasted prices, will allow us to manage the current low-price environment. At the same time, we remain incredibly optimistic about the long-term outlook for natural gas. We are laser-focused on our strategy of consolidating mature assets at attractive multiples while enhancing our margins through vertical integration of the energy value chain from production to retirement. We have built a company that provides safe, reliable, and responsibly produced energy while delivering meaningful value to shareholders."
F...

Hot Stocks

07:16 EDT EU passenger car registrations up 11.5% in February - In February, the EU passenger car market continued to perform well, growing by 11.5% to 802,763 units, said the European Automobile Manufacturers Association. "However, it is important to note the low base of comparison due to the semiconductor shortage crisis at the beginning of 2022," the group said. Publicly traded automakers include Ford (F), General Motors (GM), Honda (HMC), Mercedes-Benz Group (DDAIF), Nissan (NSANY), Stellantis (STLA), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY).
SKYT FORM

Hot Stocks

07:15 EDT SkyWater establishes cryogenic lab using FormFactor tool mitigating RTS noise - SkyWater Technology (SKYT) announced it has established a new cryogenic lab to characterize random telegraph signal or RTS noise for read-out integrated circuits ROICs . Mitigating RTS noise is crucial to improving the image quality and performance for ROIC customers in various applications such as night vision, military surveillance, and industrial and automotive thermal imaging. SkyWater's cryo lab utilizes FormFactor's (FORM) leading cryogenic probe system that enables precise on-wafer measurements in extreme environments. SkyWater partnered with the University of Tennessee at Chattanooga and Arizona State University's electrical engineering teams to develop test chips which are used to determine how much RTS noise exists for various transistor types and temperatures. From these measurements, enhancements are made for improved imaging. For ROIC customers, it is crucial to minimize RTS noise as it becomes a limiting factor to image sensor performance. SkyWater's cryo lab detects and measures noise which enables mitigation efforts for RTS effects. The new cryogenic noise characterization capabilities at SkyWater further enhance the company's ability to streamline process and product development for advanced imaging systems in both defense and specialty industrial applications.
CFMS

Hot Stocks

07:14 EDT Conformis launches patient awareness campaign for knee replacements - Conformis recently launched a patient education and awareness campaign in selected U.S. markets to strengthen the importance of patient choice by highlighting the differences between traditional "off-the-shelf" products and truly personalized knee systems that offer clinically proven benefits to patients. The campaign is currently airing in the Boston, MA and Minneapolis-St. Paul, MN metro areas in an effort to educate future patients about their options when it comes to total knee replacement surgery. Independent surveys and Conformis market research show that most of the growing total knee replacement patient population is unaware of stark differences in knee replacement systems, and simply receives the brand of knee replacement system used most frequently by their surgeon. Conformis makes fully personalized or patient specific knee systems for each patient using advanced 3D imaging technology, which is designed to produce an implant that matches each patient's unique anatomy, and is designed to offer multiple benefits to patients and medical facilities that have been demonstrated in peer-reviewed clinical studies: Patients reporting significant higher fulfillment of their expectations regarding post-op function and knee strength. Significant bone sparing as compared to traditional total knee arthroplasty. Lower total direct costs for hospital admissions, with variables such as operative time and length of stay favoring fully personalized implants.
LTHCF

Hot Stocks

07:14 EDT Lithium Ionic reports assay results from Bandeira property - Lithium Ionic reports assay results from its 100%-owned Bandeira property as part of an ongoing 30,000 metre drill program at the Itinga Project, located within the Aracuai district in the state of Minas Gerais, Brazil. The Company has drilled over 20,000 metres to date. Blake Hylands, Chief Executive Officer of Lithium Ionic, commented, "These results are the widest and most significant intercepts we have seen to date at Bandeira... We continue to aggressively drill Bandeira with the objective of delivering an initial NI 43-101 resource estimate in the next quarter, which will form the basis for the development of a feasibility study in the second half of the year. The Bandeira property is evolving rapidly as we continue to systematically test and delineate spodumene mineralization in 12 separate pegmatites that extend up to 1 kilometre along strike and individual mineralized dikes up to 17 metres wide..."
COYA

Hot Stocks

07:14 EDT Coya Therapeutics reports data from COYA 302 study - Coya Therapeutics reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to ameliorate disease progression. Four ALS patients with a mean decline of -1.1 points/month in the Revised ALS Functional Rating Scale, or ALSFRS-R, score prior to study initiation, were treated for 48 consecutive weeks with COYA 302 and were evaluated for safety and tolerability, Treg suppressive function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the ALSFRS-R scale. Following the administration of COYA 302 for 48 weeks, patients were evaluated over an 8-week washout period. During the 48-week treatment period, COYA 302 appeared to be well tolerated. The most common adverse event was mild injection-site reactions. No patient discontinued the study, and no deaths or other serious adverse events were reported. Preliminary efficacy of COYA 302 was measured by the ALSFRS-R scale, a validated rating tool for monitoring the progression of disability in patients with ALS. The mean ALSFRS-R scores at week 24 and week 48 after initiation of treatment with COYA 302 were not statistically different compared to the ALSFRS-R score at baseline, indicating significant amelioration in the progression of the disease over the 48-week treatment period. Treg suppressive function, expressed as percentage of inhibition of proinflammatory T cell proliferation, showed a statistically significant increase over the course of the treatment period and was significantly reduced at the end of the 8-week washout post-treatment period. Treg suppressive function at 24 weeks and 48 weeks were significantly higher compared to baseline, suggesting enhanced and durable Treg suppressive function over the course of treatment. In contrast, Treg suppressive function was significantly decreased at the end of the 8-week washout period compared to end-of-treatment at week 48. The study also evaluated serum biomarkers of inflammation, oxidative stress, and lipid peroxides. The available data up to 16 weeks after initiation of treatment suggest a decrease of these biomarker levels, which is consistent with the observed enhancement of Treg function. The evaluation of the full biomarker data is ongoing.
DBTX QURE

Hot Stocks

07:12 EDT Decibel Therapeutics appoints Matthew Kapusta to board of directors - Decibel Therapeutics (DBTX) announced the appointment of Matthew Kapusta to its Board of Directors. Matthew Kapusta has 25 years of experience in the life sciences industry and currently serves as Chief Executive Officer and Director of uniQure (QURE), a global gene therapy company.
PYR

Hot Stocks

07:11 EDT PyroGenesis announces Paterson joins company as General Counsel - Separately, PyroGenesis is pleased to announce today that Mark Paterson has joined the Company as General Counsel. Paterson is a senior business lawyer with comprehensive corporate and commercial experience, including in senior in-house roles as well as private practice.
PYR

Hot Stocks

07:11 EDT PyroGenesis receives $507,500 purchase order for three plasma torches - PyroGenesis Canada announces that the Company has received an order for three waste-destructing plasma torches from the US Navy's shipbuilder, Newport News Shipbuilding. The three plasma torches ordered are for the USS Gerald R. Ford aircraft carrier, the largest and most technologically advanced warship ever built, valued at approximately $13B. The plasma torches are to be used in PyroGenesis' proprietary Plasma Arc Waste Destruction System, PAWDS, that the Company previously built and delivered to the US Navy. The USS Gerald R. Ford conducted its maiden mission in fall 2022, during which the ship tested operational systems on board, including the Company's PAWDS. Following the mission's successful completion, Newport News Shipbuilding - the sole designer and builder of US Navy aircraft carriers - ordered the three additional plasma torches as well as ancillary components. The value of these new orders is approximately $507,500. Final delivery is scheduled for Q3 2023.
CLBT

Hot Stocks

07:11 EDT Cellebrite launches PathfinderX capabilities - Cellebrite DI announced the global launch of Pathfinder X, an elevated suite of artificial intelligence-enabled capabilities for a wide variety of digital data from various sources designed to provide enhanced connectivity capabilities and valuable insights to agencies and teams working through complex investigations. Pathfinder X now offers: Cloud deployment options on AWS and Azure VPC. A hub and spoke deployment format ideal for geographically dispersed teams. A new user management system with audit trails and group assignments to ensure enhanced security and compliance with government and Federal security requirements, including FISMA.
TLSA

Hot Stocks

07:10 EDT Tiziana Life Sciences announces purchase of common shares by chairman - Tiziana Life Sciences announces that it has been notified that Gabriele Cerrone, its Chairman and Acting CEO, purchased 7,500 common shares at $0.79 per share, bringing his total holding to 38,693,237 common shares.
BGNE

Hot Stocks

07:09 EDT BeiGene enters new phase to expand U.S. R&D capacity in NJ - BeiGene is entering a new phase as it continues to build its U.S. presence. The company announced that the last piece of structural steel will be laid at its Hopewell, NJ campus This new facility will provide state-of-the-art commercial-stage U.S. biologic pharmaceutical manufacturing, late-stage research and clinical development capabilities that complement the company's existing capabilities around the world... " The new campus will have approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing space with the ability to add 600,000 more over time. First announced in 2021, BeiGene's investment in this project is expected to total approximately $700 million. Construction is expected to be complete next year.
ACRHF CGC

Hot Stocks

07:09 EDT Acreage obtains final order for strategic arrangement with Canopy Growth - Acreage Holdings has obtained a final order from the Supreme Court of British Columbia approving the previously announced arrangement under section 288 of the Business Corporations Actinvolving Canopy Growth Corporation and Canopy USA. The implementation of the Floating Share Arrangement is subject to the satisfaction or waiver of all other conditions set out in the arrangement agreement dated October 24, 2022, as amended on March 17, 2023, among the Company, Canopy and Canopy USA. Pursuant to the Floating Share Arrangement, Canopy USA will acquire all of the issued and outstanding Class D subordinate voting shares of Acreage on the basis of 0.45 of a common share of Canopy for each Floating Share held at the time of the acquisition of the Floating Shares. In accordance with the terms of the Floating Share Arrangement Agreement, Canopy has agreed, subject to the terms and conditions set forth therein, to exercise its option pursuant to the arrangement agreement between Canopy and Acreage dated April 18, 2019, as amended to acquire Acreage's outstanding Class E subordinate voting shares, representing approximately 70% of the total shares of Acreage as at the date hereof, at a fixed exchange ratio of 0.3048 of a Canopy Share for each Fixed Share held, such exercise to occur no later than five business days following the satisfaction of all required conditions. Upon completion of: the acquisition of the Floating Shares pursuant to the Floating Share Arrangement; and the acquisition of the Fixed Shares pursuant to the arrangement under section 288 of the BCBCA on the terms and conditions set out in the Existing Arrangement Agreement, Canopy USA will own 100% of the issued and outstanding shares in the capital of Acreage. As previously announced, Acreage received the required approval of the holders of Floating Shares in connection with the Floating Share Arrangement at its special meeting of Floating Shareholders held on March 15, 2023. Upon the satisfaction or waiver of all other conditions set out in the Floating Share Arrangement Agreement, which the parties continue to work towards, the parties will complete the Floating Share Arrangement. On March 17, 2023, Acreage, Canopy and Canopy USA entered into an amendment to the Floating Share Arrangement Agreement to extend the Exercise Outside Date from March 31, 2023 to May 31, 2023, or such later date as may be agreed to in writing by Acreage, Canopy and Canopy USA.
TLRY

Hot Stocks

07:09 EDT Tilray announces Montauk Brewing expands distribution across Northeast - Tilray Brands announced the northeast expansion of Montauk Brewing Company. Montauk Brewing is now available in over 3,500 points of distribution, across New York, New Jersey, Connecticut, and Rhode Island including top national retailers. Ty Gilmore, President, U.S. Beer at Tilray Brands, said, "Growing Montauk Brewing's distribution across the northeast in New York and New Jersey and expanding into new states including Connecticut, and Rhode Island was a strategic first step in our expansion plan. Montauk Brewing has enormous potential to grow into a true national brand and we will continue to leverage our existing nationwide infrastructure to expand the brand's distribution and growth through innovation for all channels and consumers, building a diversified portfolio while giving our fans what they want."
IRON

Hot Stocks

07:08 EDT Disc Medicine announces collaboration with NIH for Phase 2 study of bitopertin - Disc Medicine announced a collaboration with the National Heart Lung and Blood Institute, NHLBI, of the National Institutes of Health, NIH, to evaluate bitopertin, a therapeutic candidate designed to modulate heme biosynthesis, in a phase 2 clinical study of patients with Diamond-Blackfan anemia, DBA. The study will be conducted and funded by the NIH under a Cooperative Research and Development Agreement, CRADA, and is expected to initiate mid-year 2023. "We're thrilled to have the support of the NHLBI for this clinical trial as there is growing evidence to suggest that reducing excess levels of heme may be an effective treatment strategy for DBA. This collaboration will enable us to benefit from the experience of the NHLBI in designing and conducting clinical studies of DBA." said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. "Disc now has ongoing development programs of bitopertin in both erythropoietic porphyria and DBA. We believe controlling heme synthesis has the potential to address a wide range of hematologic conditions and are planning studies in additional indications." Under the CRADA, the NHLBI will serve as the regulatory sponsor and be responsible for conducting a phase 2 clinical study of bitopertin in DBA patients. The study will be jointly funded by the NHLBI and Disc.
WTTR

Hot Stocks

07:07 EDT Select Energy Services authorizes new $50M share repurchase program - Select Energy Services has authorized a new $50M share repurchase program under which the company may repurchase its outstanding shares of Class A common stock. This new authorization is in addition to the $8.6M remaining outstanding under the company's previous $25M authorization, as of December 31, 2022. The combined outstanding repurchase authorization represents nearly 10% of the Company's outstanding Class A common stock. Repurchases may be suspended or discontinued at any time without prior notice. The Company expects to fund the repurchase program out of working capital and cash flow from operations, as well as borrowings under its sustainability-linked credit facility.
ALT

Hot Stocks

07:06 EDT Altimmune announces reuslts from interim analysis of MOMENTUM Phase 2 trial - Altimmune announced topline results from a Week 24 interim analysis of 160 subjects in its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide along with the results of the 12-week Phase 1b safety trial of pemvidutide in subjects with obesity or overweight and type 2 diabetes. The MOMENTUM Phase 2 obesity trial is being conducted at 30 sites across the U.S. The trial was designed to enroll approximately 320 subjects with obesity or overweight with at least one co-morbidity and without diabetes. Subjects were randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise. At Week 24, subjects receiving pemvidutide achieved mean weight losses of 7.3%, 9.4% and 10.7% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, with the placebo group experiencing a mean weight loss of 1.0%. An impact of baseline body weight was observed, where subjects with baseline body weight less than or equal to 115 kg achieved mean weight losses of 8.2%, 10.6%, 11.9% and 0.8% at the 1.2 mg, 1.8 mg, 2.4 mg and placebo groups, respectively. Approximately 50% of subjects achieved 10% or more weight loss and approximately 20% of subjects achieved 15% or more weight loss at Week 24 at the 1.8 mg and 2.4 mg doses. Regarding safety, upper GI events of nausea and vomiting comprised the majority of AEs. These events were predominantly mild and moderate in severity, dose-related and similar in frequency to those observed in prior trials of pemvidutide. Rates of lower GI AEs including diarrhea and constipation were notably low. Treatment discontinuation rates were 28.2% in subjects receiving placebo and 24.0% in subjects receiving pemvidutide. The majority of placebo discontinuations were due to withdrawal of consent, while approximately half of the withdrawals across the pemvidutide dose groups were attributed to GI AEs. Phase 1b Type 2 Diabetes Safety Trial: The Phase 1b trial, which was conducted to evaluate the safety profile of pemvidutide in subjects with overweight or obesity and type 2 diabetes, was comprised of 54 subjects randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 12 weeks. Subjects receiving pemvidutide achieved mean weight losses of 4.4%, 6.1% and 7.7% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, over only 12 weeks of treatment, with the placebo group experiencing a mean weight gain of 0.8%.
ALGM

Hot Stocks

07:05 EDT Allegro MicroSystems adds two switching regulators to ClearPower solutions - Allegro MicroSystems announced the addition of two switching regulators to their ClearPower module solutions-the APM81803 and the APM81911 for highly electrified industrial and automotive applications. These thermally optimized, highly integrated switching regulator modules facilitate a rapid, reduced-cost path to electromagnetic compatibilities while reducing printed circuit board footprint by 70% compared to conventional discrete solutions.
PLUG

Hot Stocks

07:04 EDT Plug Power expands GenKey offering for warehouse with electric forklifts - Plug Power has expanded its GenKey offering to enable fuel cell adoption for warehouses that operate fewer than 100 electric forklifts. For the first time, this segment of the forklift market, representing more than 25% of all forklifts sold in the U.S., will have access to cost-effective hydrogen fuel cells and the increased productivity they unlock. Plug is removing the barriers that fleets with 40 to 100 forklifts have previously seen, including capital, labor, space constraints and the challenges associated with hydrogen fuel sourcing and delivery. Customers that operate fewer than 100 electric forklifts can easily adopt hydrogen fuel cells, while increasing productivity, reducing space and carbon emissions. Plug's solutions are incentivized by the Inflation Reduction Act, which has significantly lowered the cost of green hydrogen. Fuel cells also benefit from federal tax credits.
BB

Hot Stocks

07:01 EDT BlackBerry to sell non-core patents, applications to Malikie for $900M - BlackBerry announced that it has entered into an agreement to sell substantially all of its , a newly-formed subsidiary of Key Patent Innovations Limited, or KPI, an intellectual property monetization company, for a combination of cash at closing and potential future royalties in the aggregate amount of up to $900M. The transaction is not subject to any financing conditions. Funding has been secured from a US-based investment firm, with in excess of $30B of assets under management. Under the terms of the agreement, BlackBerry will receive $170M in cash on closing and an additional $30M in cash by no later than the third anniversary of closing. BlackBerry will also be entitled to receive annual cash royalties from the profits generated from the BlackBerry patents, on the following basis: 8% of the first $500M of profits; 15% of the next $250M of profits; 30% of the next $250M of profits; and 50% of all subsequent profits. Royalty payments to BlackBerry will initially be capped at $700M, subject to an annual cap increase of an amount equal to 4% of the remaining portion of the $700M that has not been paid to BlackBerry as of the date of the increase. Malikie's costs will also be capped in the calculation of profits generated. Approximately 32,000 patents and applications relating primarily to mobile devices, messaging and wireless networking will be sold in the transaction with Malikie. The transaction excludes patents and applications that are necessary to support BlackBerry's current core business operations. It also excludes approximately 120 monetizable non-core patent families relating to mobile devices, as well as all existing revenue generating agreements. BlackBerry will receive a license back to the patents being sold and the transaction will not impact customers' use of any of BlackBerry's products, solutions or services. Completion of the transaction is conditional upon, among other things, satisfaction of all regulatory conditions under the Hart-Scott-Rodino Antitrust Improvements Act in the United States and the Investment Canada Act.
MX

Hot Stocks

06:57 EDT MagnaChip begins mass production of MOSFET1 - Magnachip announced that the company began full-scale mass production of its new 40V MXT Metal-Oxide-Semiconductor Field-Effect Transistor, or MOSFET1, optimized for the Electric Water Pumps, or EWPs, and Electric Oil Pumps, or EOPs, in electric vehicles, or EVs.
PLX

Hot Stocks

06:55 EDT Protalix doses first patient in PRX-115 trial - Protalix announced that the first patient has been dosed in the company's phase I First in Human, or FIH, clinical trial of PRX-115, the company's recombinant PEGylated uricase product candidate under development as a potential treatment of severe gout.
BWXT

Hot Stocks

06:46 EDT BWX Technologies awarded engineering contract from GE Hitachi Nuclear Energy - BWX Technologies announced an engineering contract awarded by GE Hitachi Nuclear Energy for its BWRX-300 small modular reactor reactor pressure vessel. The RPV, which contains the reactor core and associated internals, comprises the largest component within the BWRX-300. Work associated with the contract includes engineering analysis, design support, manufacturing and procurement preparations.
MOD REVG

Hot Stocks

06:35 EDT Modine Manufacturing expands thermal management partnership with Rev Group - Modine Manufacturing (MOD) announced an expansion of its partnership with REV Group (REVG) and its fire apparatus manufacturing brands E-ONE, KME, Ferrara and Spartan Emergency Response. Modine will supply its EVantage thermal management systems for the Vector(TM), the first North American-style all-electric fire truck.
BEAM

Hot Stocks

06:34 EDT Beam Therapeutics names Gopi Shanker, Ph.D., as Chief Scientific Officer - Beam Therapeutics announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer. Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities. Dr. Shanker will report to Giuseppe Ciaramella, Ph.D., president of Beam, who has broad oversight of Beam's research, manufacturing, regulatory, quality and pharmaceutical sciences organizations.
MREO

Hot Stocks

06:34 EDT Mereo BioPharma provides regulatory updates on alvelestat for lung disease - Mereo BioPharma announced regulatory feedback following recent end-of-Phase 2 meetings with the FDA and the European Medicines Agency related to its alvelestat program for the treatment of alpha-1-antitrypsin deficiency-associated lung disease - AATD-LD -. Based on clear recommendations from the FDA and the EMA, the company is designing a single, global, Phase 3 study evaluating the 240 mg dose of alvelestat versus placebo in patients with AATD-LD to support applications for full marketing approvals in both the U.S. and EU. The company's proposed Phase 3 study has two independent primary endpoints, i) a Patient-Reported Outcome, as guided by the FDA, and ii) lung density measured by CT scan, as guided by the EMA. Mereo is exploring potential partnerships to fund the Phase 3 study. If successful, this proposed Phase 3 study, with an expected duration of 12-18 months and an enrollment target of approximately 200 patients, is expected to support full regulatory approvals in both the U.S. and EU without an additional confirmatory trial. This could provide the company with a path to full approval of alvelestat based on a Phase 3 trial similar in size and length to what would be required for an accelerated or conditional approval based on biomarkers.
STVN TMO

Hot Stocks

06:33 EDT Stevanato Group announces partnership with Thermo Fisher - Stevanato Group (STVN) announced its collaboration with Thermo Fisher Scientific (TMO) to bring to the market a fully integrated on-body delivery system platform for subcutaneous administration. The semi-reusable drug delivery device will provide micro-precision basal doses and full-content bolus injections as a highly flexible and customizable platform for administering a wide range of therapies. The collaboration brings the ability to deliver small molecules and biologics, including large volumes, subcutaneously at home, closer to patients, improving adherence and effectiveness of pharmacological treatments. Along with the proprietary device platform, Stevanato Group will offer pre-sterilized EZ-fill cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services.
DCO

Hot Stocks

06:31 EDT Ducommun to acquire BLR Aerospace, terms not disclosed - Ducommun announced that it entered into a definitive securities purchase agreement to acquire BLR Aerospace, on March 20. The Transaction is subject to customary closing conditions and regulatory approval, and is expected to be completed during the second quarter of 2023. Founded in 1992, BLR is a provider of aerodynamic systems that enhance the productivity, performance and safety of rotary- and fixed-wing aircraft on commercial and military platforms. Ducommun intends to finance the acquisition through its existing revolving credit facility.
DXCM

Hot Stocks

06:02 EDT DexCom announces expanded coverage for G6 CGM System in Manitoba - Dexcom announced that its Dexcom G6 CGM System will be available to people of all ages with type 1 and type 2 diabetes in Manitoba who meet eligibility criteria. Expanding coverage for rtCGM to include all eligible patients with type 1 or type 2 diabetes establishes Manitoba as the leader among Canadian provinces. As of this announcement, Manitoba is currently the only province in Canada that does not require an application for preapproval of coverage which means improved access for patients and reduced workload for prescribers. The ease of access for rtCGM systems is now raising the bar for other jurisdictions across Canada to follow suit.
PRGO

Hot Stocks

05:40 EDT Perrigo recalls some Gerber baby formula due to possible contamination - Perrigo last week announced the recall of several batches of Gerber brand baby formula because of the possible presence of a common bacteria. The recall involves certain lots of Gerber Good Start SoothePro powdered formula that were made in January at its plant in Eau Claire, Wisconsin, Perrigo said, adding that "This product is being recalled out of an abundance of caution due to the potential presence of Cronobacter sakazakii." Perrigo said: "No distributed product has tested positive for the presence of this bacteria, no adverse events have been reported and no other products manufactured at this facility or any other of Perrigo's facilities are affected by this recall." Reference Link
IBM

Hot Stocks

05:31 EDT IBM, Cleveland Clinic unveil private sector quantum computer - Cleveland Clinic and IBM officially unveiled the first deployment of an onsite private sector IBM-managed quantum computer in the United States. The IBM Quantum System One installed at Cleveland Clinic will be the first quantum computer in the world to be uniquely dedicated to healthcare research with an aim to help Cleveland Clinic accelerate biomedical discoveries.
ACN

Hot Stocks

05:28 EDT Accenture to acquire Flutura, terms undisclosed - Accenture has agreed to acquire industrial artificial intelligence, or AI, company Flutura, headquartered in Bangalore, India. Flutura will strengthen Accenture's industrial AI services to increase the performance of plants, refineries, and supply chains while also enabling clients to accomplish their net zero goals faster. Accenture plans to bring Flutura's capabilities to clients in the energy, chemicals, metals, mining, and pharmaceutical industries. Terms of this deal were not disclosed.
REGN SNY

Hot Stocks

05:26 EDT Regeneron, Sanofi announce EC approval of Dupixent - Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent in the European Union, or EU, to treat severe atopic dermatitis in children aged six months to five years old who are candidates for systemic therapy. With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.
ELLO

Hot Stocks

05:24 EDT Ellomay Capital enters JDA to develop solar photovoltaic projects in Texas - Ellomay Capital announced its entry into a joint development agreement for the development of solar photovoltaic projects in the State of Texas. The JDA was executed with a project development company experienced in the development of energy projects, site acquisition, capital markets and commercial management. The JDA provides for the initial development, design, construction and finance of two solar PV projects with aggregate projected DC capacity of 23 MW. The First Projects are in advanced stages of development and the estimated capital costs of the First Projects are in the range of $25M-$27M. The company's share of the capital costs of the First Projects is estimated at approximately $18M-$20M and the balance is intended to be provided by tax equity sources with whom the company is currently in discussions. The sites for the First Projects will be leased under long-term leases from special purpose companies controlled by the development team. One of the First Projects, with a DC capacity of approximately 13 MW, is expected to achieve Ready to Build status within six months. The JDA also provides for the development of three additional solar PV projects up to Ready to Build status with aggregate DC capacity of approximately 30 MW. The projects to be developed under the JDA will be subject to the ERCOT Distributed Generation Scheme for projects of up to 10 MW AC capacity and the applicable electricity market is the "ERCOT North" zone market. Under the DG Scheme, ERCOT, allows owners of generation assets to sell electricity to Qualified Service Entities at market rates under Real Time or Day Ahead prices at the local nodes where the projects are located and/or to designated "Behind the Meter" clients under power purchase agreements.
SELB

Hot Stocks

05:19 EDT Selecta Biosciences, Sobi announce DISSOLVE I and II meet primary endpoinr - Selecta Biosciences and Sobi announced topline results from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials to determine safety and efficacy of two different dose levels of SEL-212 in adult patients with chronic refractory gout. DISSOLVE I met its primary endpoint, with 56% of patients receiving monthly doses of SEL-212 at 0.15 mg/kg achieving a response. The DISSOLVE II also met its primary endpoint, with 47% receiving monthly doses of SEL-212 at 0.15 mg/kg achieving a response. SEL-212 is a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme. Detailed results from the DISSOLVE I and DISSOLVE II trials are expected to be presented at an upcoming medical meeting. Regulatory submission in the U.S. is anticipated in the first half of 2024. Sobi licensed SEL-212 from Selecta in June 2020 and is responsible for development, regulatory and commercial activities in all markets outside of China. Selecta is responsible for ImmTOR manufacturing. The Phase 3 program for SEL-212 was run by Selecta and funded by Sobi. Under the terms of the agreement with Sobi, Selecta is eligible to receive additional development and regulatory milestone payments totaling $65 million and up to an additional $550M in commercial milestones. Selecta is also eligible to receive tiered double-digit royalties on sales.